<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1810234396
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VULTERA 200 mg Film Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VORICONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2334.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMATHEN INTERNATIONAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMATHEN INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vultera&nbsp;contains the active substance&nbsp;voriconazole.&nbsp;Vultera&nbsp;is an antifungal medicine. It&nbsp;works by killing or stopping the growth of the fungi that cause infections.&nbsp;</p><p>&nbsp;</p><p>It is used for the treatment of patients (adults and children over the age of 2) with:&nbsp;</p><ul><li><p>Invasive&nbsp;aspergillosis&nbsp;(a type of fungal infection due to&nbsp;Aspergillus&nbsp;sp.),&nbsp;</p></li><li><p>Candidaemia&nbsp;(another type of fungal infection due to&nbsp;Candida sp.) in non-neutropenic&nbsp;patients (patients without abnormally low white blood cells count),&nbsp;</p></li><li><p>Serious invasive&nbsp;Candida sp.&nbsp;infections when the fungus is resistant to&nbsp;fluconazole&nbsp;(another antifungal medicine),&nbsp;</p></li><li><p>Serious fungal infections caused by&nbsp;Scedosporium&nbsp;sp.&nbsp;or&nbsp;Fusarium&nbsp;sp. (two different&nbsp;species of fungi).&nbsp;</p></li></ul><p>&nbsp;</p><p>Vultera&nbsp;is intended for:&nbsp;</p><ul><li><p>Patients with worsening, possibly life-threatening, fungal infections.&nbsp;</p></li></ul><p>&nbsp;</p><ul><li><p>Prevention of fungal infections in high risk bone marrow transplant recipients.&nbsp;</p></li></ul><p>&nbsp;</p><p>This product should only be taken under the supervision of a doctor.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take&nbsp;Vultera:&nbsp;</p><ul><li><p>If you are allergic to&nbsp;voriconazole&nbsp;or any of the other ingredients of&nbsp;this medicine&nbsp;(listed in section 6);&nbsp;</p></li></ul><p>&nbsp;</p><p>It is very important that you inform your doctor or pharmacist if you are taking or have taken any other medicines, even those that are obtained without a prescription, or herbal medicines.&nbsp;</p><p>&nbsp;</p><p>The medicines in&nbsp;the following&nbsp;list must not be taken during your course of&nbsp;Vultera&nbsp;treatment:&nbsp;</p><ul><li><p>Terfenadine&nbsp;(used for allergy),&nbsp;</p></li><li><p>Astemizole&nbsp;(used for allergy),&nbsp;</p></li><li><p>Cisapride&nbsp;(used for stomach problems),&nbsp;</p></li></ul><ul><li><p>Pimozide&nbsp;(used for treating mental illness),&nbsp;</p></li><li><p>Quinidine&nbsp;(used for irregular heart beat),&nbsp;</p></li><li><p>Rifampicin&nbsp;(used for treating tuberculosis),&nbsp;</p></li><li><p>Efavirenz&nbsp;(used for treating HIV) in doses of 400 mg and above once daily,&nbsp;</p></li><li><p>Carbamazepine&nbsp;(used to treat seizures),&nbsp;</p></li></ul><ul><li><p>Phenobarbital (used for severe insomnia and seizures),&nbsp;</p></li><li><p>Ergot alkaloids (e.g. ergotamine,&nbsp;dihydroergotamine; used for migraine),&nbsp;</p></li><li><p>Sirolimus&nbsp;(used in transplant patients),&nbsp;</p></li><li><p>Ritonavir&nbsp;(used for treating HIV) in doses of 400mg and more twice daily,&nbsp;</p></li><li><p>St John&rsquo;s&nbsp;Wort&nbsp;(herbal supplement).&nbsp;</p></li></ul><p>&nbsp;</p><p>Warnings and precautions&nbsp;</p><p>Talk to your doctor&nbsp;or&nbsp;pharmacist&nbsp;before taking&nbsp;Vultera&nbsp;:&nbsp;</p><ul><li><p>If&nbsp;you have had an allergic reaction to other azoles;&nbsp;</p></li><li><p>If&nbsp;you are suffering from, or have ever suffered from liver disease. If you have liver&nbsp;disease, your doctor may prescribe a lower dose of&nbsp;Vultera&nbsp;. Your doctor should&nbsp;also monitor your liver function while you are being treated with&nbsp;Vultera&nbsp;&nbsp;by doing&nbsp;blood tests;&nbsp;</p></li></ul><ul><li><p>If&nbsp;you are known to have&nbsp;cardiomyopathy, irregular&nbsp;heart beat, slow heart rate or&nbsp;an abnormality&nbsp;of electrocardiogram (ECG) called &lsquo;long&nbsp;QTc&nbsp;syndrome&rsquo;.&nbsp;</p></li></ul><p>&nbsp;</p><p>You should avoid&nbsp;any&nbsp;sunlight and sun exposure while being treated. It is important to cover sun&nbsp;exposed areas of skin and use sun&nbsp;screen with high sun protection factor (SPF), as an&nbsp;increased sensitivity of skin to the sun&rsquo;s UV rays can occur. These precautions are also&nbsp;applicable to children.&nbsp;</p><p>&nbsp;</p><p>While being treated with&nbsp;Vultera, tell&nbsp;your doctor immediately if you develop:&nbsp;</p><ul><li><p>Sunburn,&nbsp;</p></li><li><p>Severe skin rash or blisters,&nbsp;</p></li><li><p>Bone&nbsp;pain.&nbsp;</p></li></ul><p>&nbsp;</p><p>If you develop skin disorders as described above, your doctor may refer you to a&nbsp;dermatologist, who after consultation may decide that it is important for you to be seen on a&nbsp;regular basis. There is a small chance that skin cancer could develop with long term use of&nbsp;Vultera.&nbsp;</p><p>&nbsp;</p><p>Your doctor should monitor the function of your liver and kidney by doing blood tests.&nbsp;</p><p>&nbsp;</p><p>Children and adolescents&nbsp;</p><p>Vultera&nbsp;should not be given to children&nbsp;younger than 2 years&nbsp;of&nbsp;age.&nbsp;</p><p>&nbsp;</p><p>Other medicines and&nbsp;Vultera&nbsp;&nbsp;</p><p>Please tell&nbsp;your doctor or pharmacist if you are taking,&nbsp;have recently taken&nbsp;or might take any other medicines.&nbsp;</p><p>&nbsp;</p><p>Some medicines, when taken at the same time as&nbsp;Vultera,&nbsp;may affect the way&nbsp;Vultera&nbsp;works&nbsp;or&nbsp;Vultera&nbsp;may&nbsp;affect the way they work.&nbsp;</p><p>&nbsp;</p><p>Tell your doctor if you are taking the following medicine, as treatment with&nbsp;Vultera&nbsp;at the&nbsp;same time should be avoided if possible:&nbsp;</p><ul><li><p>Ritonavir&nbsp;(used for treating HIV) in doses of 100 mg twice daily.&nbsp;</p></li></ul><p>&nbsp;</p><p>Tell your doctor if you are taking&nbsp;either&nbsp;of the&nbsp;following medicines, as treatment with&nbsp;Vultera&nbsp;at the same time should be avoided if possible, and a dose adjustment of&nbsp;voriconazole&nbsp;may be required:&nbsp;</p><ul><li><p>Rifabutin&nbsp;(used for treating tuberculosis). If you are already being treated with&nbsp;rifabutin&nbsp;your blood counts and side effects to&nbsp;rifabutin&nbsp;will need to be monitored.&nbsp;</p></li><li><p>Phenytoin&nbsp;(used to treat epilepsy). If you are already being treated with&nbsp;phenytoin&nbsp;your&nbsp;blood concentration of&nbsp;phenytoin&nbsp;will need to be&nbsp;monitored during your treatment&nbsp;with&nbsp;Vultera&nbsp;and your dose may be adjusted.&nbsp;</p></li></ul><p>&nbsp;</p><p>Tell your doctor if you are taking any of the following medicines, as a dose adjustment or&nbsp;monitoring may be required to check that the medicines and/ or&nbsp;Vultera&nbsp;are still having the&nbsp;desired effect:&nbsp;</p><ul><li><p>Warfarin&nbsp;and other anticoagulants (e.g.&nbsp;phenprocoumon,&nbsp;acenocoumarol; used to slow&nbsp;down clotting of the blood),&nbsp;</p></li></ul><ul><li><p>Ciclosporin&nbsp;(used in transplant patients),&nbsp;</p></li><li><p>Tacrolimus&nbsp;(used in transplant patients),&nbsp;</p></li><li><p>Sulphonylureas&nbsp;(e.g.&nbsp;tolbutamide,&nbsp;glipizide, and&nbsp;glyburide) (used for diabetes),&nbsp;</p></li><li><p>Statins&nbsp;(e.g.&nbsp;atorvastatin,&nbsp;simvastatin) (used for lowering cholesterol),&nbsp;</p></li><li><p>Benzodiazepines (e.g&nbsp;midazolam,&nbsp;triazolam) (used for severe insomnia and stress),&nbsp;</p></li></ul><ul><li><p>Omeprazole&nbsp;(used for treating ulcers),&nbsp;</p></li><li><p>Oral contraceptives (if you take&nbsp;Vultera&nbsp;whilst using oral contraceptives, you may get&nbsp;side effects such as nausea and menstrual disorders),&nbsp;</p></li><li><p>Vinca&nbsp;alkaloids (e.g.&nbsp;vincristine&nbsp;and&nbsp;vinblastine) (used in treating cancer),&nbsp;</p></li><li><p>Indinavir&nbsp;and other HIV protease inhibitors (used for treating HIV),&nbsp;</p></li><li><p>Non-nucleoside reverse transcriptase inhibitors (e.g.&nbsp;efavirenz,&nbsp;delavirdine,&nbsp;nevirapine)(used for treating HIV) (some doses of&nbsp;efavirenz&nbsp;can&nbsp;not&nbsp;be taken at the same time as&nbsp;Vultera&nbsp;),&nbsp;</p></li></ul><ul><li><p>Methadone (used to treat heroin addiction),&nbsp;</p></li><li><p>Alfentanil&nbsp;and&nbsp;fentanyl&nbsp;and other short acting opiates such as&nbsp;sufentanil&nbsp;(pain&nbsp;killers&nbsp;used for surgical procedures),&nbsp;</p></li><li><p>Oxycodone&nbsp;and other long acting opiates such as&nbsp;hydrocodone&nbsp;(used for moderate to&nbsp;severe pain),&nbsp;</p></li><li><p>Non-steroidal anti-inflammatory drugs (e.g. ibuprofen,&nbsp;diclofenac) (used for treating&nbsp;pain and inflammation),&nbsp;</p></li><li><p>Fluconazole&nbsp;(used for fungal infections),&nbsp;</p></li></ul><ul><li><p>Everolimus&nbsp;(used for treating advanced kidney cancer and in transplant patients).&nbsp;</p></li></ul><p>&nbsp;</p><p>Pregnancy and breast-feeding&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor&nbsp;or pharmacist&nbsp;for advice before taking this medicine.&nbsp;</p><p>&nbsp;</p><p>Vultera&nbsp;must not be taken during pregnancy, unless indicated by your doctor. Effective&nbsp;contraception must be used in women of childbearing potential. Contact your doctor&nbsp;immediately if you become pregnant while taking&nbsp;Vultera.&nbsp;</p><p>&nbsp;</p><p>Vultera&nbsp;must not be used during breast-feeding. Ask your doctor or pharmacist for advice before taking any medicine whilst breast-feeding.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Driving and using machines&nbsp;</p><p>Vultera&nbsp;may cause blurring of vision or uncomfortable sensitivity to light. While&nbsp;affected, do not drive or operate any tools or machines.&nbsp;Contact&nbsp;your doctor if you&nbsp;experience this.&nbsp;</p><p>&nbsp;</p><p>Vultera&nbsp;contains lactose&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars,&nbsp;tell&nbsp;your doctor before taking&nbsp;this medicinal product.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor&nbsp;has told you. Check with your doctor or&nbsp;pharmacist if you are not sure.&nbsp;</p><p>&nbsp;</p><p>Your doctor will determine your dose depending on your weight and the type of infection you&nbsp;have.&nbsp;</p><p>&nbsp;</p><p>The recommended dose for adults (including elderly patients) is as follows:&nbsp;</p><p>&nbsp;</p><table border="1"><tbody><tr><td rowspan="2" colspan="1"><p>&nbsp;</p></td><td colspan="2"><p>Tablets&nbsp;</p></td></tr><tr><td><p>Patients 40 kg and above&nbsp;</p></td><td><p>Patients less than 40 kg&nbsp;</p></td></tr><tr><td><p>Dose for the first 24&nbsp;</p><p>hours&nbsp;(Loading Dose)&nbsp;</p></td><td><p>400 mg every 12 hours&nbsp;</p><p>for the first 24 hours&nbsp;</p></td><td><p>200 mg every 12 hours&nbsp;</p><p>for the first 24 hours&nbsp;</p></td></tr><tr><td><p>Dose after the first 24&nbsp;</p><p>hours&nbsp;(Maintenance Dose)&nbsp;</p></td><td><p>200 mg twice a day&nbsp;</p></td><td><p>100 mg twice a day&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Depending on your response to treatment, your doctor may increase the daily dose to 300mg twice a day.&nbsp;</p><p>&nbsp;</p><p>The doctor may decide to decrease the dose if you have mild to moderate cirrhosis.&nbsp;</p><p>&nbsp;</p><p>Use in children and adolescents&nbsp;</p><p>The recommended dose for children and teenagers is as follows:&nbsp;</p><p>&nbsp;</p><table border="1"><tbody><tr><td rowspan="2" colspan="1"><p>&nbsp;</p></td><td colspan="2"><p>Tablets&nbsp;</p></td></tr><tr><td><p>Children aged 2 to less&nbsp;than 12 years and&nbsp;teenagers aged 12 to 14&nbsp;years weighing less than&nbsp;50 kg&nbsp;</p></td><td><p>Teenagers aged 12 to 14&nbsp;years weighing 50 kg or&nbsp;more; and all teenagers&nbsp;older than 14&nbsp;years.&nbsp;</p></td></tr><tr><td><p>Dose for the first 24&nbsp;</p><p>hours&nbsp;(Loading Dose)&nbsp;</p></td><td><p>Your treatment will be&nbsp;started as an infusion&nbsp;</p></td><td><p>400 mg every 12 hours&nbsp;for the first 24 hours&nbsp;</p></td></tr><tr><td><p>Dose after the first 24&nbsp;</p><p>hour&nbsp;(Maintenance Dose)&nbsp;</p></td><td><p>9 mg/kg twice a day&nbsp;</p><p>(a maximum dose of 350&nbsp;</p><p>mg twice daily)&nbsp;</p></td><td><p>200 mg twice a day&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Depending on your response to treatment, your doctor may increase or decrease the daily&nbsp;dose.&nbsp;</p><p>&nbsp;</p><p>Tablets must only be given if the child is able to swallow tablets.&nbsp;</p><p>&nbsp;</p><p>Take&nbsp;your&nbsp;tablet at least one hour before, or one hour after a meal. Swallow the tablet&nbsp;whole with some water.&nbsp;</p><p>&nbsp;</p><p>If you or your child are taking&nbsp;Vultera&nbsp;for prevention of fungal infections, your doctor may stop giving&nbsp;Vultera&nbsp;if you or your child develop treatment related side effects.&nbsp;</p><p>&nbsp;</p><p>If you take more&nbsp;Vultera&nbsp;than you should&nbsp;</p><p>If you take more tablets than prescribed (or if someone else takes your tablets) you must seek&nbsp;medical advice or go to the nearest hospital casualty department immediately. Take&nbsp;your&nbsp;box&nbsp;of&nbsp;Vultera&nbsp;tablets with you. You may experience abnormal intolerance to light as a result of&nbsp;taking more&nbsp;Vultera&nbsp;than you should.&nbsp;</p><p>&nbsp;</p><p>If you forget to take&nbsp;Vultera&nbsp;&nbsp;</p><p>It is important to take your&nbsp;Vultera&nbsp;tablets regularly at the same time each day. If you&nbsp;forget to take one dose, take your next dose when it is due. Do not take a double dose to&nbsp;make up for a forgotten dose.&nbsp;</p><p>&nbsp;</p><p>If you stop taking&nbsp;Vultera&nbsp;&nbsp;</p><p>It has been shown that taking all doses at the appropriate times may greatly increase the&nbsp;effectiveness of your medicine. Therefore unless your doctor instructs you to stop treatment,&nbsp;it is important to keep taking&nbsp;Vultera&nbsp;correctly, as described above.&nbsp;</p><p>&nbsp;</p><p>Continue taking&nbsp;Vultera&nbsp;until your doctor tells you to stop. Do not stop treatment early&nbsp;because your infection may not be cured. Patients with a weakened immune system or those&nbsp;with difficult infections may require long term treatment to prevent the infection from&nbsp;returning.&nbsp;</p><p>&nbsp;</p><p>When&nbsp;Vultera&nbsp;treatment is stopped by your doctor you should not experience any effects.&nbsp;</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor&nbsp;or&nbsp;pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets&nbsp;them.&nbsp;</p><p>&nbsp;</p><p>If any side effects occur, most are likely to be minor and temporary. However, some maybe serious and need medical attention.&nbsp;</p><p>&nbsp;</p><p>Serious side effects&nbsp;</p><p>Stop taking&nbsp;Vultera&nbsp;and see a doctor immediately&nbsp;if you experience:&nbsp;</p><ul><li><p>Rash;&nbsp;</p></li><li><p>Jaundice&nbsp;or&nbsp;changes in blood tests of liver function;&nbsp;</p></li><li><p>Pancreatitis.&nbsp;</p></li></ul><p>&nbsp;</p><p>Other side effects&nbsp;</p><p>&nbsp;</p><p>Very common&nbsp;(may affect more than 1 in 10 people):&nbsp;</p><ul><li><p>Visual&nbsp;impairment&nbsp;(change in vision),&nbsp;</p></li></ul><ul><li><p>Fever,&nbsp;</p></li><li><p>Rash,&nbsp;</p></li><li><p>Nausea, vomiting,&nbsp;diarrhea,&nbsp;</p></li><li><p>Headache,&nbsp;</p></li><li><p>Swelling of the extremities,&nbsp;</p></li></ul><ul><li><p>Stomach pains,&nbsp;</p></li><li><p>Breathing difficulties.&nbsp;</p></li></ul><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people):&nbsp;</p><ul><li><p>Flu-like symptoms,&nbsp;irritation and inflammation of the gastrointestinal tract,&nbsp;inflammation of the sinuses,&nbsp;inflammation of the gums,&nbsp;chills, weakness,&nbsp;</p></li></ul><ul><li><p>Low numbers of&nbsp;some types of&nbsp;red or&nbsp;white blood cells,&nbsp;low numbers of cells called platelets that help the blood to clot,&nbsp;</p></li><li><p>Allergic reaction or exaggerated immune response,&nbsp;</p></li><li><p>Anxiety, depression, confusion, agitation,&nbsp;inability to sleep,&nbsp;hallucinations,&nbsp;&nbsp;</p></li><li><p>Seizures, tremors or uncontrolled muscle movements, tingling or abnormal skin&nbsp;sensations, increase in muscle tone, sleepiness, dizziness,&nbsp;</p></li><li><p>Bleeding in the eye,&nbsp;</p></li></ul><ul><li><p>Heart rhythm problems including very fast heartbeat, very slow heartbeat, fainting,&nbsp;</p></li><li><p>Low blood pressure, inflammation of a vein (which may be associated with the&nbsp;formation of a blood clot),&nbsp;</p></li><li><p>Breathing difficulty, chest pain,&nbsp;swelling of the face,&nbsp;fluid accumulation in the lungs,&nbsp;</p></li><li><p>Constipation, indigestion, inflammation of the lips,&nbsp;</p></li><li><p>Low blood sugar, low blood potassium,&nbsp;low sodium in the blood,&nbsp;</p></li></ul><ul><li><p>Jaundice,&nbsp;inflammation of the liver,&nbsp;redness of the skin,&nbsp;</p></li><li><p>Skin rashes which may lead to severe blistering and peeling of the skin characterized by a flat, red&nbsp;area on the skin that is covered with small confluent bumps,&nbsp;</p></li><li><p>Itchiness,&nbsp;</p></li><li><p>Hair loss,&nbsp;</p></li><li><p>Back pain,&nbsp;</p></li></ul><ul><li><p>Kidney failure, blood in the urine, changes in kidney function&nbsp;tests.&nbsp;</p></li></ul><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people):&nbsp;</p><ul><li><p>Inflammation of the gastrointestinal tract causing antibiotic associated diarrhea, inflammation of the&nbsp;lymphatic vessels,&nbsp;</p></li><li><p>Inflammation of the thin tissue that lines the inner wall of the abdomen and covers the abdominal&nbsp;organ,&nbsp;</p></li></ul><ul><li><p>Enlarged lymph glands (sometimes painful),disorder of blood clotting system, failure of blood&nbsp;marrow, other blood cell changes (increased&nbsp;eosinophil&nbsp;and low white blood cells in blood),&nbsp;</p></li><li><p>Abnormal brain function, Parkinson-like symptoms, nerve injury resulting in numbness, pain,&nbsp;tingling&nbsp;or burning in the hands or feet,&nbsp;</p></li><li><p>Depressed function of the adrenal gland,&nbsp;underactive thyroid gland,&nbsp;</p></li><li><p>Problems&nbsp;with&nbsp;balance or&nbsp;coordination,&nbsp;</p></li><li><p>Swelling of the brain,&nbsp;</p></li></ul><ul><li><p>Double vision&nbsp;serious conditions of the eye including:&nbsp;pain and inflammation of the eyes and eyelids, involuntary movement&nbsp;of the eye, abnormal eye movement, damage to the optic nerve resulting in vision impairment, optic disc swelling,&nbsp;</p></li><li><p>Decreased sensitivity to touch,&nbsp;</p></li><li><p>Abnormal sense of taste,&nbsp;</p></li><li><p>Hearing difficulties, ringing in the ears, vertigo,&nbsp;</p></li><li><p>Inflammation of certain internal&nbsp;organs- pancreas and duodenum,&nbsp;swelling and inflammation of the tongue,&nbsp;</p></li></ul><ul><li><p>Enlarged liver, liver failure, gallbladder disease, gallstones,&nbsp;</p></li><li><p>Joint&nbsp;inflammation, inflammation of the veins under the skin (which may be associated with the formation of a blood clot),&nbsp;pain,&nbsp;</p></li><li><p>Inflammation of the kidney, proteins in the urine,&nbsp;</p></li><li><p>Very fast heart rate or skipped heartbeats,&nbsp;</p></li><li><p>Abnormal electrocardiogram (ECG),&nbsp;</p></li></ul><ul><li><p>Blood&nbsp;cholesterol increased, blood urea increased,&nbsp;</p></li><li><p>Allergic skin reactions (sometimes severe), including widespread blistering rash and skin peeling, inflammation of the skin, the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and sub&nbsp;mucosal tissues, itchy or sore patches of thick, red skin with silvery scales of skin, hives, sunburn or severe skin reaction following exposure to light or sun, skin redness and irritation, red or purple discoloration of the skin which may be caused by low platelet count, eczema,&nbsp;</p></li><li><p>Injection site reaction,&nbsp;</p></li><li><p>Life threatening allergic reaction.&nbsp;</p></li></ul><p>Rare (may affect up to 1 in 1,000 people):&nbsp;</p><ul><li><p>Overactive thyroid gland&nbsp;</p></li><li><p>Deterioration of brain function that is a serious complication of liver disease&nbsp;</p></li><li><p>Damage to the optic nerve resulting in vision impairment, clouding of the cornea&nbsp;</p></li><li><p>Bullous&nbsp;photosensitivity&nbsp;</p></li><li><p>A disorder in which the body&rsquo;s immune system attacks part of the peripheral nervous system&nbsp;</p></li></ul><ul><li><p>Severe heart rhythm problems that may be life threatening&nbsp;</p></li></ul><p>Other significant side effects whose frequency is not known, but should be reported to your doctor immediately:&nbsp;</p><ul><li><p>Skin cancer&nbsp;</p></li><li><p>Inflammation of the tissue surrounding the bone&nbsp;</p></li><li><p>Red, scaly patches or ring-shaped skin lesions that may be a symptom of an autoimmune disease called&nbsp;cutaneous&nbsp;lupus&nbsp;erythematosus&nbsp;&nbsp;</p></li></ul><p>As&nbsp;Vultera&nbsp;has&nbsp;been known to affect the liver and&nbsp;the kidney, your doctor should&nbsp;monitor the function of your liver and kidney by doing&nbsp;blood tests. Please&nbsp;ask&nbsp;your&nbsp;doctor if you have any stomach pains or if your stools have a different consistency.&nbsp;</p><p>There have been reports of skin cancer in patients treated with&nbsp;Vultera for&nbsp;long periods of&nbsp;time.&nbsp;</p><p>Sunburn or severe skin reaction following exposure to light or sun was experienced more frequently in children. If you or your child develops skin disorders, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you or your child to be seen on a regular basis.&nbsp;</p><p>If any of these side effects persist or are troublesome, please tell your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the&nbsp;carton after EXP. The expiry date&nbsp;refers to the last day of that month.&nbsp;</p><p>Store below 30C.&nbsp;</p><p>Bottles:&nbsp;Use within 30 days&nbsp;after first opening&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist&nbsp;how to throw away medicines you no longer use. These&nbsp;measures will help protect the&nbsp;environment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li><p>The active substance is&nbsp;voriconazole. Each tablet contains&nbsp; 200 mg&nbsp;voriconazole&nbsp;.</p></li></ul><ul><li><p>The other ingredients are&nbsp;lactose monohydrate, pre&nbsp;gelatinised&nbsp;starch&nbsp;(maize starch),&nbsp;croscarmellose&nbsp;sodium, povidoneK30,&nbsp;silica&nbsp;colloidal anhydrous,&nbsp;magnesium&nbsp;stearate&nbsp;and&nbsp;opadry&nbsp;II white OY-LS 28908.&nbsp;</p></li></ul><p>&nbsp;</p><p>The&nbsp;opadry&nbsp;II white OY-LS 28908&nbsp;coating&nbsp;contains:&nbsp;HPMC/Hypromellose&nbsp;(3cP, 15cP and 50&nbsp;cP)&nbsp;(E464),&nbsp;titanium dioxide (E171),&nbsp;lactose monohydrate&nbsp;and&nbsp;macrogol&nbsp;4000/PEG (E1521).&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vultera 200 mg film-coated tablets are supplied as white to off-white oval biconvex tablets with "V200"marked on one side, 15.7±0.2 mm in length and 7.9±0.2 mm in width. 

 Vultera 200 mg film-coated tablets are supplied in PVC/Aluminum blister available in packs of 30 tablets or in white opaque HDPE bottle with a polypropylene child resistant screw cap, containing 30 tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by:&nbsp;</p><p>Pharmathen International Greece&nbsp;&nbsp;</p><p>For:&nbsp;</p><p>SPIMACO&nbsp;</p><p>AlQassim&nbsp;pharmaceutical plant&nbsp;</p><p>Saudi Pharmaceutical Industries &amp;&nbsp;</p><p>Medical Appliance Corporation&nbsp;</p><p>Saudi Arabia&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2015.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>فولتيرا&nbsp;يحتوى&nbsp;على المادة الفعالة&nbsp;فوريكونازول.&nbsp;فولتيرا&nbsp;هو دواء مضاد للفطريات. يعمل هذا الدواء من خلال قتل أو إيقاف نمو الفطريات المسببة للعدوى.&nbsp;</p><p>يستخدم هذا الدواء لعلاج المرضى (البالغين والأطفال الأكبر&nbsp;فى&nbsp;العمر&nbsp;من سنتين) المصابين&nbsp;بأى&nbsp;مما&nbsp;يلى:&nbsp;</p><ul><li><p>داء&nbsp;الرشاشيات&nbsp;الغازية&nbsp;(وهو&nbsp;نوع&nbsp;من&nbsp;العدوى&nbsp;الفطرية&nbsp;المسببة بواسطة نوع من فطر&nbsp;الرشاشيات),&nbsp;</p></li></ul><ul><li><p>المبيضات&nbsp;في&nbsp;الدم&nbsp;(نوع&nbsp;آخر&nbsp;من&nbsp;العدوى&nbsp;الفطرية&nbsp;المسببة بواسطة نوع من فطر المبيضات)&nbsp;في&nbsp;المرضى&nbsp;الغير مصابين بنقص&nbsp;العدلات&nbsp;(بمعنى المرضى&nbsp;الغير مصابين بنقص غير&nbsp;طبيعى&nbsp;فى&nbsp;عدد خلايا الدم البيضاء),&nbsp;</p></li><li><p>عدوى المبيضات الخطيرة المتوغلة&nbsp;والتى&nbsp;تكون مقاومة لعقار&nbsp;فلوكونازول&nbsp;(وهو نوع آخر من الأدوية المضادة&nbsp;للفطريات),&nbsp;&nbsp;</p></li><li><p>العدوى&nbsp;الفطرية&nbsp;الخطيرة&nbsp;الناجمة&nbsp;عن&nbsp;فطر&nbsp;البوغانة&nbsp;أو&nbsp;فطر&nbsp;الفيوزاريوم&nbsp;(وهما نوعان مختلفان من الفطريات).&nbsp;&nbsp;</p></li></ul><p>يستخدم&nbsp;فولتيرا&nbsp;فى&nbsp;الحالات الآتية:&nbsp;</p><ul><li><p>فى&nbsp;حالة المرضى المصابين بتفاقم العدوى الفطرية&nbsp;والتى&nbsp;قد تهدد الحياة.&nbsp;</p></li></ul><ul><li><p>للوقاية من العدوى الفطرية لدى المرضى الخاضعين لزرع النخاع العظمى المعرضين للخطر الشديد للإصابة بالعدوى.&nbsp;</p></li></ul><p>يجب تناول هذا الدواء فقط تحت إشراف الطبيب.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول أقراص&nbsp;فولتيرا&nbsp;فى&nbsp;الحالات الآتية:&nbsp;</p><ul><li><p>إذا كنت مصاباً بفرط التحسس تجاه مادة&nbsp;فوريكونازول&nbsp;أو&nbsp;أى&nbsp;من المكونات الأخرى لهذا الدواء (والمذكورة&nbsp;فى&nbsp;الفقرة&nbsp;6).&nbsp;</p></li></ul><p>من&nbsp;الضرورى&nbsp;عليك إبلاغ طبيبك المعالج أو&nbsp;الصيدلى&nbsp;بشأن&nbsp;أى&nbsp;أدوية أخرى تتناولها&nbsp;حالياً&nbsp;أو تناولتها&nbsp;مؤخراً,&nbsp;بما فيها تلك الأدوية&nbsp;التى&nbsp;حصلت عليها بدون وصفة طبية أو الأدوية العشبية.&nbsp;</p><p>يجب&nbsp;عدم تناول&nbsp;الأدوية&nbsp;الموجودة&nbsp;في&nbsp;القائمة&nbsp;التالية&nbsp;خلال&nbsp;فترة العلاج بواسطة&nbsp;فولتيرا:&nbsp;</p><ul><li><p>ترفينادين&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج الحساسية),&nbsp;</p></li><li><p>أستيميزول&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج الحساسية),&nbsp;</p></li><li><p>سيسابريد&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج&nbsp;مشاكل&nbsp;المعدة),&nbsp;</p></li></ul><ul><li><p>بيموزيد&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج&nbsp;الأمراض&nbsp;العقلية),&nbsp;</p></li><li><p>كينيدين&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج&nbsp;عدم&nbsp;انتظام&nbsp;ضربات&nbsp;القلب),&nbsp;</p></li><li><p>ريفامبيسين&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج&nbsp;السل),&nbsp;</p></li><li><p>إيفافيرنز&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج&nbsp;فيروس&nbsp;نقص&nbsp;المناعة&nbsp;البشرية)&nbsp;في&nbsp;جرعات&nbsp;من&nbsp;400&nbsp;ملجم&nbsp;فما فوق&nbsp;مرة&nbsp;واحدة&nbsp;يومياً,&nbsp;</p></li><li><p>كاربامازيبين&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج&nbsp;النوبات&nbsp;التشنجية),&nbsp;</p></li></ul><ul><li><p>فينوباربيتال&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج الأرق&nbsp;الشديد&nbsp;والنوبات),&nbsp;</p></li><li><p>قلويدات&nbsp;الشقران&nbsp;(مثل&nbsp;إرجوتامين,&nbsp;ثنائي&nbsp;هيدرو&nbsp;إرجوتامين,&nbsp;والتى&nbsp;تستخدم&nbsp;لعلاج الصداع&nbsp;النصفي),&nbsp;</p></li><li><p>سايروليموس&nbsp;(المستخدم&nbsp;في&nbsp;حالة المرضى&nbsp;ذوى&nbsp;زرع&nbsp;الأعضاء),&nbsp;</p></li><li><p>ريتونافير&nbsp;(والذى&nbsp;يستخدم&nbsp;لعلاج&nbsp;فيروس&nbsp;نقص&nbsp;المناعة&nbsp;البشرية)&nbsp;في&nbsp;جرعات&nbsp;من&nbsp;400&nbsp;ملجم&nbsp;فما فوق&nbsp;مرتين&nbsp;يومياً,&nbsp;</p></li><li><p>نبتة&nbsp;سانت&nbsp;جون&nbsp;(دواء عشبي).&nbsp;</p></li></ul><p>&nbsp;</p><p>تحذيرات&nbsp;واحتياطات&nbsp;</p><p>تحدث&nbsp;إلى&nbsp;طبيبك&nbsp;المعالج&nbsp;أو&nbsp;الصيدلي&nbsp;قبل&nbsp;تناول أقراص&nbsp;فولتيرا&nbsp;فى&nbsp;الحالات الآتية:&nbsp;</p><ul><li><p>إذا&nbsp;كان&nbsp;لديك&nbsp;حساسية&nbsp;تجاه&nbsp;الأزولات&nbsp;الأخرى,&nbsp;</p></li><li><p>إذا&nbsp;كنت&nbsp;تعاني&nbsp;حالياً أو مسبقاً&nbsp;فى&nbsp;أي&nbsp;وقت&nbsp;مضى&nbsp;من&nbsp;أمراض&nbsp;الكبد.&nbsp;حيث أنه&nbsp;إذا&nbsp;كان&nbsp;لديك&nbsp;مرض&nbsp;بالكبد,&nbsp;فقد&nbsp;يصف&nbsp;لك&nbsp;الطبيب&nbsp;المعالج&nbsp;جرعة&nbsp;أقل&nbsp;من&nbsp;فولتيرا.&nbsp;يجب&nbsp;على&nbsp;طبيبك&nbsp;المعالج&nbsp;أيضاً&nbsp;مراقبة&nbsp;وظائف&nbsp;الكبد&nbsp;الخاصة&nbsp;بك&nbsp;أثناء فترة علاجك بواسطة&nbsp;فولتيرا&nbsp;بإجراء&nbsp;اختبارات&nbsp;الدم.&nbsp;</p></li></ul><ul><li><p>إذا كان&nbsp;من&nbsp;المعروف&nbsp;لديك أنك&nbsp;تعانى&nbsp;من&nbsp;اعتلال&nbsp;عضلة&nbsp;القلب&nbsp;أو&nbsp;عدم&nbsp;انتظام&nbsp;ضربات&nbsp;القلب أو&nbsp;بطء&nbsp;فى&nbsp;معدل&nbsp;ضربات&nbsp;القلب&nbsp;أو&nbsp;وجود خلل&nbsp;فى&nbsp;رسم&nbsp;القلب&nbsp;الكهربائي&nbsp;(ECG)&nbsp;يسمى&nbsp;&quot;متلازمة&nbsp;إطالة الفترة&nbsp;QTc&quot;.&nbsp;</p></li></ul><p>يجب&nbsp;تجنب&nbsp;آشعة&nbsp;الشمس&nbsp;وتجنب&nbsp;التعرض&nbsp;للشمس&nbsp;أثناء&nbsp;فترة العلاج بواسطة&nbsp;فولتيرا.&nbsp;من&nbsp;المهم&nbsp;تغطية&nbsp;المناطق&nbsp;المعرضة&nbsp;للشمس&nbsp;من&nbsp;الجلد&nbsp;واستخدام&nbsp;واقي&nbsp;من&nbsp;الشمس&nbsp;ذو&nbsp;عامل&nbsp;عالي&nbsp;للحماية&nbsp;من&nbsp;الشمس&nbsp;(SPF),&nbsp;حيث قد تزداد&nbsp;حساسية&nbsp;الجلد&nbsp;لآشعة&nbsp;الشمس&nbsp;فوق&nbsp;البنفسجية.&nbsp;هذه&nbsp;الاحتياطات&nbsp;تنطبق&nbsp;على&nbsp;الأطفال&nbsp;أيضاً.&nbsp;</p><p>أثناء العلاج بواسطة أقراص&nbsp;فولتيرا,&nbsp;أخبر&nbsp;طبيبك&nbsp;المعالج&nbsp;فوراً&nbsp;فى&nbsp;حالة تعرضك&nbsp;لأى&nbsp;مما يلى:&nbsp;</p><ul><li><p>حروق&nbsp;الشمس,&nbsp;</p></li><li><p>طفح&nbsp;جلدي&nbsp;شديد&nbsp;أو&nbsp;بثور,&nbsp;</p></li></ul><ul><li><p>ألم&nbsp;بالعظام.&nbsp;</p></li></ul><p>فى&nbsp;حالة تعرضك لاضطرابات بالجلد كما هو مذكور&nbsp;أعلاه,&nbsp;قد يحيلك طبيبك المعالج إلى طبيب متخصص بالأمراض الجلدية, والذى قد يقرر بعد الزيارة أنه من&nbsp;الضرورى&nbsp;لك المتابعة معه بشكل منتظم. حيث قد تكون&nbsp;هناك&nbsp;فرصة&nbsp;ضئيلة لحدوث&nbsp;سرطان&nbsp;الجلد&nbsp;مع&nbsp;استخدام&nbsp;فولتيرا&nbsp;على&nbsp;المدى&nbsp;الطويل.&nbsp;</p><p>يجب على طبيبك المعالج مراقبة وظائف الكبد ووظائف الكلى من خلال إجراء اختبارات الدم.&nbsp;</p><p>الأطفال والمراهقين&nbsp;</p><p>يجب عدم تناول أقراص&nbsp;فولتيرا&nbsp;فى&nbsp;حالة الأطفال الأقل&nbsp;فى&nbsp;العمر من سنتين.&nbsp;</p><p>أقراص&nbsp;فولتيرا&nbsp;والأدوية الأخرى&nbsp;</p><p>فضلاً أخبر طبيبك المعالج أو&nbsp;الصيدلى&nbsp;بشأن&nbsp;أى&nbsp;أدوية أخرى تتناولها حالياً أو تناولتها مؤخراً أو قد تتناولها.&nbsp;</p><p>حيث عند تناول بعض الأدوية بالتزامن مع تناول أقراص&nbsp;فولتيرا&nbsp;قد يؤثر&nbsp;فولتيرا&nbsp;على طريقة عمل بعض الأدوية وقد يتأثر أيضاً ببعض الأدوية الأخرى.&nbsp;</p><p>أخبر طبيبك المعالج&nbsp;فى&nbsp;حالة تناولك&nbsp;لهذا&nbsp;الدواء,&nbsp;حيث يجب تجنب تناول&nbsp;فولتيرا&nbsp;فى&nbsp;نفس وقت&nbsp;تناول هذا&nbsp;الدواء&nbsp;إن أمكن ذلك:&nbsp;</p><ul><li><p>ريتونافير&nbsp;(والذى&nbsp;يستخدم لعلاج فيروس نقص المناعة البشرية) بجرعات&nbsp;100&nbsp;ملجم مرتين يومياً.&nbsp;</p></li></ul><p>أخبر طبيبك المعالج&nbsp;فى&nbsp;حالة تناولك لأى من الأدوية&nbsp;التالية,&nbsp;حيث يجب تجنب تناول&nbsp;فولتيرا&nbsp;فى&nbsp;نفس وقت تناول هذه الأدوية إن أمكن ذلك وقد يكون من المطلوب تعديل جرعة&nbsp;فوريكونازول:&nbsp;</p><ul><li><p>ريفابيوتين&nbsp;(الذي&nbsp;يستخدم&nbsp;لعلاج&nbsp;السل).&nbsp;إذا&nbsp;تم&nbsp;بالفعل&nbsp;علاجك بواسطة&nbsp;ريفابيوتين&nbsp;سوف تحتاج إلى&nbsp;رصد&nbsp;كل من تعداد خلايا الدم والأعراض الجانبية&nbsp;الخاصة&nbsp;بريفابيوتين.&nbsp;&nbsp;</p></li><li><p>فينيتوين&nbsp;(المستخدم&nbsp;لعلاج&nbsp;الصرع).&nbsp;إذا&nbsp;تم&nbsp;بالفعل&nbsp;علاجك بواسطة&nbsp;فينيتوين&nbsp;سوف تحتاج إلى رصد تركيز&nbsp;فينيتوين&nbsp;لديك بالدم أثناء العلاج بواسطة&nbsp;فولتيرا&nbsp;وقد يكون من المطلوب تعديل الجرعة.&nbsp;</p></li></ul><p>أخبر طبيبك المعالج&nbsp;فى&nbsp;حالة تناولك لأى من الأدوية&nbsp;الآتية,&nbsp;حيث قد يتطلب تعديل الجرعة أو قد يكون من المطلوب المراقبة للتأكد من استمرار الفعالية المطلوبة لتلك الأدوية و/أو&nbsp;فولتيرا:&nbsp;</p><ul><li><p>وارفارين&nbsp;ومضادات&nbsp;التخثر&nbsp;الأخرى&nbsp;(مثل&nbsp;فينوبروكومون,&nbsp;أسينوكومارول,&nbsp;وتستخدم&nbsp;لإبطاء&nbsp;تخثر&nbsp;الدم),&nbsp;</p></li></ul><ul><li><p>سيكلوسبورين&nbsp;(المستخدم&nbsp;في&nbsp;حالة&nbsp;المرضى&nbsp;ذوى&nbsp;زرع&nbsp;الأعضاء),&nbsp;</p></li><li><p>تاكروليموس&nbsp;(المستخدم&nbsp;في&nbsp;حالة&nbsp;المرضى&nbsp;ذوى&nbsp;زرع&nbsp;الأعضاء),&nbsp;</p></li><li><p>سلفونيل&nbsp;يوريا&nbsp;(مثل&nbsp;تولبيوتاميد,&nbsp;جليبيزايد,&nbsp;وجليبورايد) (التي&nbsp;تستخدم&nbsp;لمرض&nbsp;السكري),&nbsp;</p></li><li><p>الستاتين&nbsp;(مثل&nbsp;أتورفاستاتين,&nbsp;سيمفاستاتين) (التي&nbsp;تستخدم&nbsp;لخفض&nbsp;الكولسترول),&nbsp;</p></li><li><p>البنزوديازيبينات&nbsp;(على&nbsp;سبيل&nbsp;المثال&nbsp;ميدازولام,&nbsp;تريازولام) (التي&nbsp;تستخدم&nbsp;لعلاج&nbsp;الأرق&nbsp;الشديد&nbsp;والإجهاد),&nbsp;</p></li></ul><ul><li><p>أوميبرازول&nbsp;(المستخدم&nbsp;لعلاج&nbsp;القرحة),&nbsp;</p></li><li><p>وسائل&nbsp;منع&nbsp;الحمل&nbsp;عن&nbsp;طريق&nbsp;الفم&nbsp;(إذا&nbsp;كنتِ&nbsp;تتناولين&nbsp;فولتيرا&nbsp;أثناء&nbsp;استخدام&nbsp;وسائل&nbsp;منع&nbsp;الحمل&nbsp;عن&nbsp;طريق&nbsp;الفم,&nbsp;قد&nbsp;تتعرضين لأعراض جانبية مثل&nbsp;الغثيان&nbsp;واضطرابات&nbsp;الدورة&nbsp;الشهرية),&nbsp;</p></li><li><p>قلويدات&nbsp;فينكا&nbsp;(على&nbsp;سبيل&nbsp;المثال&nbsp;فينكريستين&nbsp;وفينبلاستين) (تستخدم&nbsp;في&nbsp;علاج&nbsp;السرطان),&nbsp;</p></li><li><p>عقار&nbsp;إندينافير&nbsp;ومثبطات&nbsp;الإنزيم&nbsp;البروتيني&nbsp;الأخرى&nbsp;لفيروس&nbsp;نقص&nbsp;المناعة&nbsp;البشرية&nbsp;(التي&nbsp;تستخدم&nbsp;لعلاج&nbsp;فيروس&nbsp;نقص&nbsp;المناعة&nbsp;البشرية),&nbsp;</p></li><li><p>مثبطات&nbsp;إنزيم&nbsp;النسخ&nbsp;العكسي&nbsp;غير&nbsp;نيوكليوزايد&nbsp;(على&nbsp;سبيل&nbsp;المثال&nbsp;إيفافيرنز,&nbsp;ديلافيردين,&nbsp;نيفيرابين) (التي&nbsp;تستخدم&nbsp;لعلاج&nbsp;فيروس&nbsp;نقص&nbsp;المناعة&nbsp;البشرية) (بعض&nbsp;جرعات&nbsp;من&nbsp;إيفافيرنز&nbsp;لا&nbsp;يمكن&nbsp;تناولها&nbsp;فى&nbsp;نفس وقت تناول&nbsp;فولتيرا),&nbsp;</p></li></ul><ul><li><p>الميثادون&nbsp;(يستخدم&nbsp;لعلاج&nbsp;إدمان&nbsp;الهيروين),&nbsp;</p></li><li><p>ألفينتانيل&nbsp;وفنتانيل&nbsp;وغيرها&nbsp;من&nbsp;المواد&nbsp;الأفيونية&nbsp;قصيرة&nbsp;المفعول&nbsp;مثل&nbsp;سوفينتانيل&nbsp;(وهى&nbsp;مسكنات للألم تستخدم للعمليات&nbsp;الجراحية),&nbsp;</p></li><li><p>أوكسيكودون&nbsp;وغيرها&nbsp;من&nbsp;المواد&nbsp;الأفيونية&nbsp;طويلة&nbsp;المفعول&nbsp;مثل&nbsp;هيدروكودون&nbsp;(التي&nbsp;تستخدم&nbsp;لتسكين الآلام المتوسطة إلى الشديدة),&nbsp;</p></li><li><p>الأدوية&nbsp;غير&nbsp;الستيرويدية&nbsp;المضادة&nbsp;للالتهابات&nbsp;(مثل&nbsp;إيبوبروفين,&nbsp;ديكلوفيناك) (التي&nbsp;تستخدم&nbsp;لعلاج الألم والالتهاب),&nbsp;</p></li><li><p>الفلوكونازول&nbsp;(الذى&nbsp;يستخدم لعلاج العدوى الفطرية),&nbsp;</p></li></ul><ul><li><p>إيفيروليموس&nbsp;(الذى&nbsp;يستخدم&nbsp;لعلاج&nbsp;سرطان&nbsp;الكلى&nbsp;المتقدم&nbsp;ولمرضى&nbsp;زرع&nbsp;الأعضاء).&nbsp;</p></li></ul><p>الحمل والرضاعة&nbsp;</p><p>إذا كنتِ حاملاً أو تقومين بإرضاع طفلك&nbsp;طبيعياً,&nbsp;أو تظنين بأنكِ قد تكونين&nbsp;حامل أو تخططين لإنجاب طفل,&nbsp;اسألى&nbsp;طبيبك المعالج أو&nbsp;الصيدلى&nbsp;للمشورة قبل البدء&nbsp;فى&nbsp;تناول هذا الدواء.&nbsp;</p><p>يحظر استخدام&nbsp;فولتيرا&nbsp;أثناء فترة&nbsp;الحمل,&nbsp;إلا إذا أوصى الطبيب بغير ذلك. يجب استخدام وسائل منع الحمل الفعالة للنساء المعرضة لإمكانية حدوث الحمل.&nbsp;تواصلى&nbsp;مع طبيبك المعالج فوراً إذا أصبحتِ حاملاً أثناء تناول&nbsp;فولتيرا.&nbsp;</p><p>يجب عدم تناول&nbsp;فولتيرا&nbsp;أثناء الرضاعة الطبيعية.&nbsp;اسألى&nbsp;طبيبك المعالج أو&nbsp;الصيدلى&nbsp;للمشورة قبل تناول&nbsp;أى&nbsp;أدوية أثناء الرضاعة.&nbsp;</p><p>القيادة واستخدام الآلات&nbsp;</p><p>قد يسبب&nbsp;فولتيرا&nbsp;عدم وضوح&nbsp;فى&nbsp;الرؤية أو حساسية&nbsp;بعدم&nbsp;الارتياح&nbsp;للضوء. إذا تأثرت&nbsp;بذلك,&nbsp;لا تقم بقيادة السيارة أو استخدام&nbsp;أى&nbsp;آلات أو أدوات. تواصل مع طبيبك المعالج عند تعرضك لهذه الأعراض.&nbsp;&nbsp;</p><p>فولتيرا&nbsp;يحتوى&nbsp;على لاكتوز&nbsp;</p><p>إذا تم إبلاغك من قبل طبيبك المعالج بعدم تحملك لبعض أنواع&nbsp;السكر,&nbsp;أخبر طبيبك المعالج قبل البدء&nbsp;فى&nbsp;تناول هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائماً بتناول الدواء تماماً كما أخبرك طبيبك المعالج.&nbsp;فى&nbsp;حالة عدم&nbsp;تأكدك,&nbsp;تحقق من خلال الطبيب المعالج أو&nbsp;الصيدلى.&nbsp;</p><p>سيقوم طبيبك المعالج بتحديد الجرعة المناسبة لك اعتماداً على وزنك ونوع العدوى لديك.&nbsp;</p><p>الجرعة&nbsp;الموصى&nbsp;بها للبالغين (ويشمل ذلك كبار السن من المرضى) كما&nbsp;يلى:&nbsp;</p><table border="1"><tbody><tr><td rowspan="2" colspan="1"><p>&nbsp;</p></td><td colspan="2"><p>الأقراص&nbsp;</p></td></tr><tr><td><p>فى&nbsp;حالة المرضى&nbsp;ذوى&nbsp;وزن 40 كجم فما أكثر&nbsp;</p></td><td><p>فى&nbsp;حالة المرضى الأقل&nbsp;فى&nbsp;الوزن من 40 كجم.&nbsp;</p></td></tr><tr><td><p>الجرعة الخاصة بأول 24 ساعة&nbsp;(جرعة التحميل)&nbsp;&nbsp;</p></td><td><p>400&nbsp;ملجم&nbsp;كل&nbsp;12&nbsp;ساعة&nbsp;خلال&nbsp;اليوم&nbsp;الأول&nbsp;من&nbsp;العلاج.&nbsp;</p></td><td><p>200&nbsp;ملجم&nbsp;كل&nbsp;12&nbsp;ساعة&nbsp;خلال&nbsp;اليوم&nbsp;الأول&nbsp;من&nbsp;العلاج.&nbsp;</p></td></tr><tr><td><p>الجرعة ما بعد 24 ساعة الأولى&nbsp;(جرعة الاستمرار)&nbsp;</p></td><td><p>200&nbsp;ملجم&nbsp;مرتين&nbsp;يومياً.&nbsp;</p></td><td><p>100&nbsp;ملجم&nbsp;مرتين&nbsp;يومياً.&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>اعتماداً على مدى استجابتك&nbsp;للعلاج,&nbsp;قد يلجأ طبيبك المعالج إلى زيادة الجرعة اليومية إلى 300 ملجم مرتين يومياً.&nbsp;</p><p>قد يقرر طبيبك المعالج خفض الجرعة الخاصة بك&nbsp;فى&nbsp;حالة إصابتك بتليف بالكبد خفيف إلى متوسط الدرجة.&nbsp;</p><p>الاستخدام&nbsp;فى&nbsp;حالة الأطفال والمراهقين&nbsp;</p><p>الجرعة&nbsp;الموصى&nbsp;بها&nbsp;فى&nbsp;حالة الأطفال والمراهقين&nbsp;هى&nbsp;كالتالى:&nbsp;</p><table border="1"><tbody><tr><td rowspan="2" colspan="1"><p>&nbsp;</p></td><td colspan="2"><p>الأقراص&nbsp;</p></td></tr><tr><td><p>فى&nbsp;حالة الأطفال&nbsp;فى&nbsp;سن&nbsp;مابين&nbsp;2 إلى أقل من 12 سنة والمراهقين&nbsp;فى&nbsp;سن 12 إلى 14 سنة&nbsp;ذوى&nbsp;وزن أقل من 50 كجم.&nbsp;</p></td><td><p>فى&nbsp;حالة المراهقين&nbsp;فى&nbsp;سن 12 إلى 14 سنة&nbsp;ذوى&nbsp;وزن 50 كجم أو أكثر وكل المراهقين الأكبر&nbsp;فى&nbsp;العمر من 14 سنة&nbsp;</p></td></tr><tr><td><p>الجرعة الخاصة بأول 24 ساعة&nbsp;(جرعة التحميل)&nbsp;&nbsp;</p></td><td><p>سيبدأ علاجك على هيئة تسريب بالوريد&nbsp;&nbsp;</p></td><td><p>400&nbsp;ملجم&nbsp;كل&nbsp;12&nbsp;ساعة&nbsp;خلال&nbsp;اليوم&nbsp;الأول&nbsp;من&nbsp;العلاج.&nbsp;</p></td></tr><tr><td><p>الجرعة ما بعد 24 ساعة الأولى&nbsp;(جرعة الاستمرار)&nbsp;</p></td><td><p>9&nbsp;ملجم/كجم&nbsp;مرتين&nbsp;يومياً&nbsp;(بحد&nbsp;أقصى&nbsp;350&nbsp;ملجم&nbsp;مرتين&nbsp;يومياً)&nbsp;</p></td><td><p>200&nbsp;ملجم&nbsp;مرتين&nbsp;يومياً.&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>اعتماداً على مدى استجابتك&nbsp;للعلاج,&nbsp;قد يلجأ طبيبك المعالج إلى زيادة&nbsp;أو خفض&nbsp;الجرعة اليومية&nbsp;الخاصة بك.&nbsp;</p><p>يجب إعطاء العلاج على هيئة أقراص فقط&nbsp;فى&nbsp;حالة استطاعة الطفل بلع الأقراص.&nbsp;</p><p>قم بتناول الأقراص قبل الأكل بساعة أو بعد الأكل بساعة. قم بابتلاع القرص كاملاً مع بعض الماء.&nbsp;</p><p>إذا كنت أنت أو طفلك خاضعين للعلاج بواسطة&nbsp;فولتيرا&nbsp;للوقاية من العدوى&nbsp;الفطرية,&nbsp;قد يلجأ الطبيب المعالج إلى إيقاف إعطاء هذا الدواء&nbsp;فى&nbsp;حالة تعرضك أو تعرض طفلك لأعراض جانبية متعلقة بالعلاج.&nbsp;</p><p>فى&nbsp;حالة تناول أقراص&nbsp;فولتيرا&nbsp;أكثر مما&nbsp;ينبغى&nbsp;</p><p>فى&nbsp;حالة تناولك لأقراص&nbsp;فولتيرا&nbsp;أكثر من الجرعة الموصوفة لك (أو&nbsp;فى&nbsp;حالة تناول شخص آخر لهذه الأقراص) يجب عليك البحث عن العناية الطبية أو التوجه فوراً إلى قسم الطوارئ بأقرب مستشفى. خذ معك علبة أقراص&nbsp;فولتيرا. قد تتعرض لعدم تحمل الضوء على غير المعتاد كنتيجة لتناول جرعة أكبر مما&nbsp;ينبغى&nbsp;من أقراص&nbsp;فولتيرا.&nbsp;</p><p>فى&nbsp;حالة نسيان تناول أقراص&nbsp;فولتيرا&nbsp;</p><p>من&nbsp;الضرورى&nbsp;عليك تناول أقراص&nbsp;فولتيرا&nbsp;بشكل منتظم&nbsp;فى&nbsp;نفس الوقت من كل يوم. إذا نسيت تناول الجرعة الخاصة&nbsp;بك,&nbsp;قم بتناول الجرعة التالية&nbsp;فى&nbsp;وقتها. لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية.&nbsp;</p><p>فى&nbsp;حالة التوقف عن تناول أقراص&nbsp;فولتيرا&nbsp;</p><p>ثبت&nbsp;علمياً&nbsp;أن تناول الجرعات&nbsp;فى&nbsp;أوقاتها المناسبة قد يزيد من فعالية علاجك. لذا ما لم ينصحك طبيبك المعالج بالتوقف عن تناول هذا&nbsp;الدواء,&nbsp;من&nbsp;الضرورى&nbsp;عليك الالتزام بتناول أقراص&nbsp;فولتيرا&nbsp;بشكل صحيح, كما هو موصوف أعلاه.&nbsp;</p><p>استمر&nbsp;فى&nbsp;تناول أقراص&nbsp;فولتيرا&nbsp;إلى أن يخبرك طبيبك المعالج بالتوقف عن تناول العلاج. لا تتوقف عن تناول هذا الدواء قبل الأوان حيث قد يؤدى ذلك إلى عدم زوال العدوى.&nbsp;فى&nbsp;حالة المرضى الذين لديهم ضعف&nbsp;فى&nbsp;أداء جهاز المناعة أو الذين لديهم إصابة بعدوى شديدة قد يتطلب ذلك علاج طويل المدى للوقاية من عودة العدوى مرة أخرى.&nbsp;</p><p>عندما يتم إيقاف علاجك من قبل طبيبك المعالج من المفروض عدم تعرضك&nbsp;لأى&nbsp;تأثيرات.&nbsp;</p><p>إذا&nbsp;كان&nbsp;لديك&nbsp;أي&nbsp;أسئلة&nbsp;أخرى&nbsp;عن&nbsp;استخدام&nbsp;هذا&nbsp;الدواء,&nbsp;اسأل&nbsp;طبيبك&nbsp;المعالج&nbsp;أو&nbsp;الصيدلي.&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع&nbsp;الأدوية,&nbsp;قد يسبب هذا الدواء أعراضاً جانبية, وإن لم تكن تحدث لكل من يتناول هذا الدواء.&nbsp;</p><p>فى&nbsp;حالة ظهور&nbsp;أى&nbsp;من الأعراض&nbsp;الجانبية,&nbsp;تكون معظمها أعراض خفيفة ومؤقتة. ومع&nbsp;ذلك,&nbsp;بعض هذه الأعراض قد يكون خطيراً ويحتاج إلى الرعاية الطبية.&nbsp;</p><p>الأعراض الجانبية الخطيرة&nbsp;</p><p>توقف عن تناول أقراص&nbsp;فولتيرا&nbsp;وابحث عن الرعاية الطبية فوراً إذا تعرضت&nbsp;لأى&nbsp;مما يلى:&nbsp;</p><ul><li><p>طفح&nbsp;جلدي.&nbsp;</p></li></ul><ul><li><p>مرض&nbsp;اليرقان&nbsp;أو&nbsp;تغيرات&nbsp;في&nbsp;اختبارات&nbsp;الدم&nbsp;الخاصة بوظائف&nbsp;الكبد.&nbsp;</p></li><li><p>التهاب&nbsp;البنكرياس.&nbsp;</p></li></ul><p>أعراض جانبية أخرى&nbsp;</p><p>شائعة جداً (والتى&nbsp;قد تصيب أكثر من 1 لكل 10 مستخدمين لهذا الدواء):&nbsp;</p><ul><li><p>ضعف&nbsp;البصر&nbsp;(تشوش&nbsp;في&nbsp;الرؤية),&nbsp;</p></li></ul><ul><li><p>حمى,&nbsp;</p></li><li><p>طفح&nbsp;جلدي,&nbsp;</p></li><li><p>غثيان&nbsp;وقيء&nbsp;وإسهال,&nbsp;</p></li><li><p>صداع,&nbsp;</p></li><li><p>تورم&nbsp;في&nbsp;الأطراف,&nbsp;</p></li></ul><ul><li><p>آلام&nbsp;في&nbsp;المعدة,&nbsp;</p></li><li><p>صعوبات&nbsp;في&nbsp;التنفس.&nbsp;</p></li></ul><p>شائعة (والتى&nbsp;قد تصيب&nbsp;ما يصل إلى&nbsp;1&nbsp;لكل&nbsp;10&nbsp;مستخدمين&nbsp;لهذا&nbsp;الدواء):&nbsp;</p><ul><li><p>أعراض&nbsp;شبيهة&nbsp;بأعراض&nbsp;الإنفلونزا,&nbsp;وتهيج&nbsp;والتهاب&nbsp;القناة&nbsp;الهضمية,&nbsp;والتهاب&nbsp;الجيوب&nbsp;الأنفية,&nbsp;التهاب&nbsp;اللثة,&nbsp;وقشعريرة,&nbsp;وضعف,&nbsp;</p></li><li><p>انخفاض&nbsp;فى&nbsp;أعداد&nbsp;بعض&nbsp;أنواع&nbsp;خلايا&nbsp;الدم&nbsp;الحمراء&nbsp;أو&nbsp;البيضاء,&nbsp;انخفاض&nbsp;فى&nbsp;أعداد&nbsp;الخلايا&nbsp;التى&nbsp;تسمى&nbsp;الصفائح&nbsp;الدموية&nbsp;التي&nbsp;تساعد&nbsp;على&nbsp;تجلط&nbsp;الدم,&nbsp;</p></li></ul><ul><li><p>رد&nbsp;الفعل&nbsp;التحسسي&nbsp;أو&nbsp;فرط&nbsp;فى&nbsp;استجابة&nbsp;جهاز&nbsp;المناعة,&nbsp;&nbsp;</p></li><li><p>قلق,&nbsp;واكتئاب,&nbsp;وارتباك,&nbsp;وإثارة,&nbsp;وعدم&nbsp;القدرة&nbsp;على&nbsp;النوم&nbsp;وهلوسة,&nbsp;</p></li><li><p>نوبات,&nbsp;أو رعشات&nbsp;أو&nbsp;عدم تحكم&nbsp;فى&nbsp;حركة&nbsp;العضلات,&nbsp;&nbsp;أو&nbsp;إحساس بوخز&nbsp;غير&nbsp;طبيعي&nbsp;فى&nbsp;الجلد&nbsp;وزيادة&nbsp;في&nbsp;انقباض&nbsp;العضلات,&nbsp;ونعاس&nbsp;ودوخة,&nbsp;</p></li><li><p>نزيف&nbsp;في&nbsp;العين,&nbsp;</p></li><li><p>مشاكل&nbsp;فى&nbsp;إيقاع&nbsp;القلب&nbsp;وتشمل تسارع شديد&nbsp;فى&nbsp;ضربات&nbsp;القلب&nbsp;أو&nbsp;تباطؤ&nbsp;شديد&nbsp;فى&nbsp;ضربات&nbsp;القلب&nbsp;أو&nbsp;إغماء,&nbsp;</p></li></ul><ul><li><p>انخفاض&nbsp;ضغط&nbsp;الدم,&nbsp;أو&nbsp;التهاب&nbsp;فى&nbsp;الأوردة&nbsp;(والذي&nbsp;قد&nbsp;يرتبط&nbsp;بتكوين&nbsp;تجلط&nbsp;الدم),&nbsp;</p></li><li><p>صعوبة&nbsp;في&nbsp;التنفس,&nbsp;ألم&nbsp;في&nbsp;الصدر,&nbsp;وتورم&nbsp;في&nbsp;الوجه&nbsp;وتراكم&nbsp;السوائل&nbsp;في&nbsp;الرئتين,&nbsp;</p></li><li><p>إمساك,&nbsp;وعسر&nbsp;هضم,&nbsp;والتهاب&nbsp;الشفتين,&nbsp;</p></li><li><p>انخفاض&nbsp;فى&nbsp;نسبة&nbsp;السكر&nbsp;في&nbsp;الدم,&nbsp;وانخفاض&nbsp;البوتاسيوم&nbsp;في&nbsp;الدم,&nbsp;وانخفاض&nbsp;الصوديوم&nbsp;في&nbsp;الدم,&nbsp;</p></li><li><p>اليرقان,&nbsp;والتهاب&nbsp;الكبد,&nbsp;احمرار&nbsp;في&nbsp;الجلد,&nbsp;</p></li></ul><ul><li><p>طفح&nbsp;جلدي&nbsp;والذي&nbsp;قد&nbsp;يؤدي&nbsp;إلى&nbsp;ظهور&nbsp;تقرحات&nbsp;شديدة&nbsp;وتقشير&nbsp;الجلد&nbsp;والذي&nbsp;قد يتميز بوجود&nbsp;منطقة&nbsp;حمراء&nbsp;مسطحة&nbsp;على&nbsp;الجلد&nbsp;التي&nbsp;يتم&nbsp;تغطيتها&nbsp;بنتوءات&nbsp;متموجة&nbsp;صغيرة,&nbsp;</p></li><li><p>حكة&nbsp;بالجلد,&nbsp;</p></li><li><p>تساقط&nbsp;الشعر,&nbsp;</p></li><li><p>ألم&nbsp;في&nbsp;الظهر,&nbsp;</p></li><li><p>فشل&nbsp;كلوي&nbsp;ودم&nbsp;في&nbsp;البول,&nbsp;وتغيرات&nbsp;في&nbsp;اختبارات&nbsp;وظائف&nbsp;الكلى.&nbsp;</p></li></ul><p>غير&nbsp;شائعة (والتى&nbsp;قد تصيب&nbsp;ما يصل إلى&nbsp;1&nbsp;لكل&nbsp;100&nbsp;مستخدم&nbsp;لهذا الدواء):&nbsp;</p><ul><li><p>التهاب&nbsp;القناة&nbsp;الهضمية&nbsp;مما&nbsp;يسبب&nbsp;الإسهال&nbsp;المرتبط باستخدام&nbsp;المضادات&nbsp;الحيوية&nbsp;والتهاب&nbsp;الأوعية&nbsp;الليمفاوية,&nbsp;</p></li><li><p>التهاب&nbsp;النسيج&nbsp;الرقيق&nbsp;الذي&nbsp;يبطن&nbsp;الجدار&nbsp;الداخلي&nbsp;للبطن&nbsp;ويغطي&nbsp;الأعضاء الداخلية&nbsp;فى&nbsp;منطقة&nbsp;البطن,&nbsp;</p></li><li><p>تضخم&nbsp;فى&nbsp;الغدد&nbsp;الليمفاوية&nbsp;(والذى&nbsp;يكون مؤلماً&nbsp;في&nbsp;بعض&nbsp;الأحيان),&nbsp;اضطراب&nbsp;في&nbsp;نظام&nbsp;تخثر&nbsp;الدم,&nbsp;فشل&nbsp;فى&nbsp;نخاع&nbsp;الدم,&nbsp;وتغيرات&nbsp;أخرى&nbsp;فى&nbsp;خلايا&nbsp;الدم&nbsp;(مثل&nbsp;زيادة&nbsp;الحمضات&nbsp;وانخفاض&nbsp;خلايا&nbsp;الدم&nbsp;البيضاء&nbsp;في&nbsp;الدم),&nbsp;</p></li><li><p>خلل&nbsp;فى&nbsp;وظائف&nbsp;المخ,&nbsp;وأعراض&nbsp;باركنسون&nbsp;مثل,&nbsp;إصابة&nbsp;فى&nbsp;العصب&nbsp;مما&nbsp;يؤدي&nbsp;إلى&nbsp;تنميل,&nbsp;أو ألم,&nbsp;أو إحساس بوخز&nbsp;أو&nbsp;حرق&nbsp;في&nbsp;اليدين&nbsp;أو&nbsp;القدمين,&nbsp;</p></li></ul><ul><li><p>نقص&nbsp;فى&nbsp;وظيفة&nbsp;الغدة&nbsp;الكظرية,&nbsp;أو نقص&nbsp;فى&nbsp;نشاط&nbsp;الغدة&nbsp;الدرقية,&nbsp;</p></li><li><p>مشاكل&nbsp;في&nbsp;التوازن&nbsp;أو&nbsp;التنسيق,&nbsp;</p></li><li><p>تورم&nbsp;في&nbsp;المخ,&nbsp;</p></li><li><p>ازدواج&nbsp;فى&nbsp;الرؤية&nbsp;وهى&nbsp;حالة خطيرة تتعلق بالعين وتشمل:&nbsp;ألم&nbsp;والتهاب&nbsp;فى&nbsp;العينين&nbsp;والجفون,&nbsp;وحركة غير إرادية&nbsp;للعين,&nbsp;وحركة غير طبيعية للعين,&nbsp;وتلف&nbsp;في&nbsp;العصب&nbsp;البصري&nbsp;مما&nbsp;يؤدي&nbsp;إلى&nbsp;ضعف&nbsp;الرؤية,&nbsp;و&nbsp;تورم&nbsp;فى&nbsp;القرص&nbsp;البصري,&nbsp;</p></li><li><p>انخفاض&nbsp;فى&nbsp;حساسية&nbsp;حاسة&nbsp;اللمس,&nbsp;</p></li></ul><ul><li><p>خلل&nbsp;فى&nbsp;حاسة&nbsp;التذوق,&nbsp;</p></li><li><p>صعوبات&nbsp;فى&nbsp;السمع,&nbsp;طنين&nbsp;في&nbsp;الأذنين,&nbsp;ودوار,&nbsp;</p></li><li><p>التهاب&nbsp;فى&nbsp;بعض الأعضاء الداخلية-&nbsp;البنكرياس&nbsp;والإثني&nbsp;عشر،&nbsp;وتورم&nbsp;والتهاب&nbsp;فى&nbsp;اللسان,&nbsp;</p></li><li><p>تضخم&nbsp;الكبد&nbsp;وفشل&nbsp;الكبد&nbsp;وأمراض&nbsp;المرارة,&nbsp;أو&nbsp;حصى&nbsp;في&nbsp;المرارة,&nbsp;</p></li><li><p>التهاب&nbsp;المفاصل,&nbsp;والتهاب&nbsp;في&nbsp;الأوردة&nbsp;تحت&nbsp;الجلد&nbsp;(والذي&nbsp;قد&nbsp;يرتبط بتكوين&nbsp;تجلط&nbsp;الدم),&nbsp;ألم,&nbsp;</p></li></ul><ul><li><p>التهاب&nbsp;الكلى&nbsp;وظهور&nbsp;البروتينات&nbsp;في&nbsp;البول,&nbsp;</p></li><li><p>تسارع شديد&nbsp;فى&nbsp;معدل&nbsp;ضربات&nbsp;القلب&nbsp;أو&nbsp;تفويت&nbsp;فى&nbsp;ضربات&nbsp;القلب,&nbsp;</p></li><li><p>خلل&nbsp;فى&nbsp;رسم القلب الكهربائي&nbsp;(ECG),&nbsp;</p></li><li><p>زيادة&nbsp;نسبة&nbsp;الكوليسترول&nbsp;في&nbsp;الدم,&nbsp;وزيادة&nbsp;اليوريا&nbsp;في&nbsp;الدم,&nbsp;</p></li><li><p>تفاعلات تحسسية بالجلد&nbsp;&nbsp;(والتى&nbsp;تكون&nbsp;شديدة&nbsp;في&nbsp;بعض&nbsp;الأحيان),&nbsp;بما&nbsp;في&nbsp;ذلك&nbsp;الطفح&nbsp;الجلدي&nbsp;واسع&nbsp;النطاق&nbsp;وتقشير&nbsp;الجلد,&nbsp;والتهاب&nbsp;الجلد,&nbsp;وتورم&nbsp;سريع&nbsp;فى&nbsp;الجلد&nbsp;(الوذمة)&nbsp;والأنسجة&nbsp;تحت&nbsp;الجلد&nbsp;والأنسجة&nbsp;المخاطية&nbsp;وتحت&nbsp;المخاطية,&nbsp;وبقع&nbsp;سميكة&nbsp;متقرحة مثيرة للحكة&nbsp;مع&nbsp;احمرار&nbsp;الجلد&nbsp;مع&nbsp;قشور&nbsp;فضية&nbsp;في&nbsp;الجلد,&nbsp;الشرى,&nbsp;حروق&nbsp;الشمس&nbsp;أو&nbsp;رد&nbsp;فعل&nbsp;شديد&nbsp;في&nbsp;الجلد&nbsp;بعد&nbsp;التعرض&nbsp;للضوء&nbsp;أو&nbsp;الشمس,&nbsp;واحمرار وتهيج&nbsp;الجلد,&nbsp;وتلون&nbsp;الجلد باللون&nbsp;الأحمر&nbsp;أو&nbsp;الأرجواني&nbsp;والذى&nbsp;قد يكون نتيجة&nbsp;لانخفاض&nbsp;عدد&nbsp;الصفائح&nbsp;الدموية,&nbsp;وإكزيما,&nbsp;</p></li></ul><ul><li><p>تفاعلات تحسسية بالجلد&nbsp;فى&nbsp;موقع&nbsp;الحقن,&nbsp;</p></li><li><p>تفاعلات تحسسية&nbsp;تهدد&nbsp;الحياة.&nbsp;</p></li></ul><p>نادرة (والتى&nbsp;قد تصيب&nbsp;ما يصل إلى&nbsp;1&nbsp;لكل&nbsp;1000&nbsp;مستخدم&nbsp;لهذا الدواء):&nbsp;</p><ul><li><p>فرط&nbsp;نشاط&nbsp;الغدة&nbsp;الدرقية,&nbsp;</p></li><li><p>تدهور&nbsp;فى&nbsp;وظائف&nbsp;المخ&nbsp;الذي&nbsp;هو&nbsp;من&nbsp;المضاعفات&nbsp;الخطيرة&nbsp;لأمراض&nbsp;الكبد,&nbsp;</p></li></ul><ul><li><p>تلف&nbsp;في&nbsp;العصب&nbsp;البصري&nbsp;مما&nbsp;يؤدي&nbsp;إلى&nbsp;ضعف&nbsp;الرؤية,&nbsp;ضبابية&nbsp;القرنية,&nbsp;</p></li><li><p>حساسية&nbsp;الضوء&nbsp;الفقاعية,&nbsp;</p></li><li><p>اضطراب&nbsp;يحدث نتيجة&nbsp;مهاجمة&nbsp;جهاز&nbsp;المناعة&nbsp;في&nbsp;الجسم&nbsp;لجزء&nbsp;من&nbsp;الجهاز&nbsp;العصبي&nbsp;الطرفى,&nbsp;</p></li><li><p>مشاكل&nbsp;شديدة&nbsp;فى&nbsp;ضربات&nbsp;القلب&nbsp;التي&nbsp;قد&nbsp;تهدد&nbsp;الحياة,&nbsp;</p></li></ul><p>أعراض جانبية أخرى هامة وغير معروف معدل تكرار حدوثها&nbsp;ولكن&nbsp;يجب&nbsp;إبلاغ&nbsp;الطبيب&nbsp;بها&nbsp;فوراً:&nbsp;</p><ul><li><p>سرطان&nbsp;الجلد,&nbsp;</p></li><li><p>التهاب&nbsp;الأنسجة&nbsp;المحيطة&nbsp;بالعظام,&nbsp;</p></li><li><p>ظهور بقع حمراء&nbsp;أو&nbsp;متقشرة&nbsp;بالجلد&nbsp;أو&nbsp;تقرحات&nbsp;جلدية&nbsp;على&nbsp;شكل&nbsp;خاتم&nbsp;والتى&nbsp;قد&nbsp;تكون&nbsp;من&nbsp;أعراض&nbsp;أحد&nbsp;أمراض&nbsp;المناعة&nbsp;الذاتية&nbsp;يسمى&nbsp;مرض&nbsp;الذئبة&nbsp;الحمامية&nbsp;الجلدية.&nbsp;</p></li></ul><p>كما&nbsp;أنه من&nbsp;المعروف&nbsp;أن&nbsp;أقراص&nbsp;فولتيرا&nbsp;قد&nbsp;تؤثر&nbsp;على&nbsp;الكبد&nbsp;والكلى,&nbsp;فقد يلجأ طبيبك المعالج إلى&nbsp;مراقبة&nbsp;وظيفة&nbsp;الكبد&nbsp;والكلى&nbsp;بإجراء&nbsp;اختبارات&nbsp;الدم.&nbsp;يرجى&nbsp;سؤال&nbsp;طبيبك&nbsp;المعالج&nbsp;إذا&nbsp;كان&nbsp;لديك&nbsp;أي&nbsp;آلام&nbsp;في&nbsp;المعدة&nbsp;أو&nbsp;إذا&nbsp;كان&nbsp;لديك اختلاف&nbsp;فى&nbsp;تماسك أو لزوجة&nbsp;البراز.&nbsp;</p><p>كانت&nbsp;هناك&nbsp;تقارير&nbsp;حول الإصابة بسرطان&nbsp;الجلد&nbsp;في&nbsp;المرضى&nbsp;الذين&nbsp;عولجوا&nbsp;بأقراص&nbsp;فولتيرا&nbsp;لفترة طويلة من الزمن.&nbsp;</p><p>حروق الشمس أو تفاعلات الجلد الشديدة عقب التعرض للضوء أو الشمس قد تمت ملاحظتها بمعدل أكبر&nbsp;فى&nbsp;حالة الأطفال.&nbsp;فى&nbsp;حالة تعرضك أو تعرض طفلك لاضطرابات&nbsp;بالجلد,&nbsp;قد يلجأ طبيبك المعالج إلى تحويل الحالة إلى طبيب متخصص بالجلد, والذى بعد الاستشارة قد يرى أنه من&nbsp;الضرورى&nbsp;لك أو لطفلك المتابعة معه بشكل منتظم.&nbsp;</p><p>فى&nbsp;حالة استمرار أو تفاقم&nbsp;أى&nbsp;من الأعراض&nbsp;الجانبية,&nbsp;فضلاً أخبر طبيبك المعالج بذلك.&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول ونظر الأطفال.&nbsp;</p><p>لا تقم باستخدام هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العبوة بعد كلمة&nbsp;EXP. علماً بأن تاريخ الصلاحية يشير إلى آخر يوم من الشهر المذكور.&nbsp;</p><p>يحفظ&nbsp;في درجة حرارة أقل من&nbsp;30&nbsp;درجة مئوية.&nbsp;&nbsp;</p><p>بالنسبة للزجاجات: يجب استخدام الدواء&nbsp;فى&nbsp;خلال 30 يوماً من بعد فتح العبوة لأول مرة.&nbsp;</p><p>يجب عدم التخلص من الأدوية عبر النفايات المنزلية أو مياه الصرف&nbsp;الصحى. اسأل&nbsp;الصيدلى&nbsp;بشأن كيفية التخلص من الأدوية&nbsp;التى&nbsp;لم تعد بحاجة إليها. سوف تساعد هذا التدابير على حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li><p>المادة الفعالة&nbsp;هى&nbsp;فوريكونازول.&nbsp;يحتوى&nbsp;كل قرص على 200&nbsp;ملجم من&nbsp;فوريكونازول).&nbsp;</p></li><li><p>المكونات الأخرى&nbsp;هى:&nbsp;لاكتوز أحادي&nbsp;الهيدرات,&nbsp;نشا&nbsp;(نشا&nbsp;الذرة),&nbsp;كروسكارميللوز&nbsp;الصوديوم,&nbsp;بوفيدون&nbsp;K30,&nbsp;سيليكا&nbsp;غروية&nbsp;لامائية,&nbsp;ستيارات&nbsp;مغنيسيوم&nbsp;وأوبادرى&nbsp;أبيض&nbsp;II&nbsp;.OY-LS 28908&nbsp;</p></li></ul><p>غطاء&nbsp;أوبادرى&nbsp;أبيض&nbsp;II&nbsp;OY-LS 28908&nbsp;يحتوى&nbsp;على:&nbsp;هيبروميللوز(3cP,&nbsp;15cP and 50&nbsp;cP)&nbsp;&nbsp;(E464),&nbsp;ثانى&nbsp;أكسيد تيتانيوم (E171),&nbsp;لاكتوز أحادي الهيدرات&nbsp;وماكروجول&nbsp;4000/PEG&nbsp;(E1521).&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>فولتيرا 200 ملجم أقراص مغلفة بطبقة رقيقة تتوافر على هيئة أقراص بيضاوية ثنائية التحدب لونها من أبيض إلى أبيض فاتح على أحد جانبيها علامة &quot;V200&quot;, طولها 15.7&plusmn;0.2 ملليمتر وعرضها 7.9&plusmn;0.2 ملليمتر. فولتيرا 200 ملجم أقراص مغلفة بطبقة رقيقة تتوافر فى شرائط ألومنيوم متوفرة فى عبوات تحتوى على 30 قرصاً أو يتوفر فى زجاجات بيضاء مزودة بغطاء بولى بروبيلين مقاوم للأطفال تحتوى كل زجاجة على 30 قرصاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>فارماثين&nbsp;الدولية اليونانية&nbsp;</p><p>لصالح:&nbsp;</p><p>الدوائية&nbsp;</p><p>مصنع الأدوية بالقصيم&nbsp;</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية&nbsp;</p><p>المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vultera 200 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 200 mg voriconazole.
Excipient with known effect: each tablet contains 235.08 mg lactose monohydrate.

For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet

White to off-white, oval biconvex film coated tablets, with code V200 on one side, 15.7±0.2 mm in lengthand7.9±0.2 mm in width.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:</p><p>&nbsp;</p><p>Treatment of invasive aspergillosis.</p><p>&nbsp;</p><p>Treatment of candidaemia in non-neutropenic patients.</p><p>&nbsp;</p><p>Treatment of fluconazole-resistant serious invasive <em>Candida </em>infections (including <em>C. krusei</em>).</p><p>&nbsp;</p><p>Treatment of serious fungal infections caused by <em>Scedosporium </em>spp. and <em>Fusarium </em>spp.</p><p>&nbsp;</p><p>Vultera should be administered primarily to patients with progressive, possibly life-threatening infections.</p><p><strong>&nbsp;</strong></p><p>Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.4).</p><p>&nbsp;</p><p>Vultera is also available as 200 mg film-coated tablets and 200 mg powder for solution for infusion.</p><p>&nbsp;</p><p><em>Adults</em></p><p>Therapy must be initiated with the specified loading dose regimen of either intravenous or oral Vultera to achieve plasma concentrations on Day 1 that are close to steady state. On the basis of the high oral bioavailability (96 %; see section 5.2), switching between intravenous and oral administration is appropriate when clinically indicated.</p><p>&nbsp;</p><p>Detailed information on dosage recommendations is provided in the following table:</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Intravenous</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Oral</strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients 40 kg and</p><p>above*</p></td><td style="vertical-align:top"><p>Patients less than</p><p>40 kg*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading dose</strong></p><p><strong>regimen</strong></p><p><strong>(first 24 hours)</strong></p></td><td style="vertical-align:top"><p>6 mg/kg every 12</p><p>hours</p></td><td style="vertical-align:top"><p>400 mg every 12</p><p>hours</p></td><td style="vertical-align:top"><p>200 mg every 12</p><p>hours</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance dose</strong></p><p><strong>(after first 24</strong></p><p><strong>hours)</strong></p></td><td style="vertical-align:top"><p>4 mg/kg twice daily</p></td><td style="vertical-align:top"><p>200 mg twice daily</p></td><td style="vertical-align:top"><p>100 mg twice daily</p></td></tr></tbody></table><p>*This also applies to patients aged 15 years and older.</p><p>&nbsp;</p><p><em><u>Duration of treatment</u></em></p><p>Treatment duration should be as short as possible depending on the patient&rsquo;s clinical and mycological response. Long term exposure to voriconazole greater than 180 days (6 months) requires careful assessment of the benefit-risk balance (see sections 4.4 and 5.1).</p><p><em>&nbsp;</em></p><p><em><u>Dosage adjustment</u></em><em><u> (Adults)</u></em></p><p>If patient response to treatment is inadequate, the maintenance dose may be increased to 300 mg twice daily for oral administration. For patients less than 40 kg the oral dose may be increased to 150 mg twice daily.</p><p>&nbsp;</p><p>If patients are unable to tolerate treatment at a higher dose reduce the oral dose by 50 mg steps to the 200 mg twice daily (or 100 mg twice daily for patients less than 40 kg) maintenance dose.</p><p>&nbsp;</p><p>In case of use as prophylaxis, refer below.</p><p><em>&nbsp;</em></p><p><em>Children (2 to &lt;12 years) and young adolescents with low body weight (12 to 14 years and &lt;50 kg)</em></p><p>Voriconazole should be dosed as children as these young adolescents may metabolize voriconazole more similarly to children than to adults.</p><p>The recommended dosing regimen is as follows:</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Intravenous</strong></p></td><td style="vertical-align:top"><p><strong>Oral</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading Dose Regimen</strong></p><p><strong>(first 24 hours)</strong></p></td><td style="vertical-align:top"><p>9 mg/kg every 12 hours</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance Dose</strong></p><p><strong>(after first 24 hours)</strong></p></td><td style="vertical-align:top"><p>8 mg/kg twice daily</p></td><td style="vertical-align:top"><p>9 mg/kg twice daily (a maximum dose of 350 mg</p><p>twice daily)</p></td></tr></tbody></table><p>Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescents aged 12 to &lt;17 years.</p><p>&nbsp;</p><p>It is recommended to initiate the therapy with intravenous regimen, and oral regimen should be considered only after there is a significant clinical improvement. It should be noted that an 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.</p><p>&nbsp;</p><p>These oral dose recommendations for children are based on studies in which voriconazole was administered as the powder for oral suspension. Bioequivalence between the powder for oral suspension and tablets has not been investigated in a paediatric population. Considering the assumed limited gastro-enteric transit time in paediatrics, the absorption of tablets may be different in paediatric compared to adult patients. It is therefore recommended to use the oral suspension formulation in children aged 2 to&lt;12.</p><p><em>&nbsp;</em></p><p><em>All other adolescents (12 to 14 years and &ge;50 kg; 15 to 17 years regardless of body weight)</em></p><p>Voriconazole should be dosed as adults.</p><p><em>&nbsp;</em></p><p><em><u>Dose adjustment(Children [2 to &lt;12 years] and young adolescents with low body weight [12 to 14 years and &lt;50 kg])</u></em></p><p>If patient response to treatment is inadequate, the dose may be increased by 1 mg/kg steps (or by 50 mg steps if the maximum oral dose of 350 mg was used initially). If patients are unable to tolerate treatment, reduce the dose by 1 mg/kg steps (or by 50 mg steps if the maximum oral dose of 350 mg was used initially).</p><p>&nbsp;</p><p>Use in paediatric patients aged 2 to &lt;12 years with hepatic or renal insufficiency has not been studied (see sections 4.8 and 5.2).</p><p><em>&nbsp;</em></p><p><u>Prophylaxis in Adults and Children</u></p><p>Prophylaxis should be initiated on the day of transplant and may be administered for up to 100 days. Prophylaxis should be as short as possible depending on the risk for developing invasive fungal infection (IFI) as defined by neutropenia or immunosuppression. It may only be continued up to 180 days after transplantation in case of continuing immunosuppression or graft versus host disease (GvHD) (see section 5.1).</p><p><em>&nbsp;</em></p><p><em>Dosage</em></p><p>The recommended dosing regimen for prophylaxis is the same as for treatment in the respective age groups. Please refer to the treatment tables above.</p><p><em>Duration of prophylaxis</em></p><p>The safety and efficacy of voriconazole use for longer than 180 days has not been adequately studied in clinical trials.</p><p>Use of voriconazole in prophylaxis for greater than 180 days (6 months) requires careful assessment of the benefit-risk balance (see sections 4.4 and 5.1).</p><p><u>The following instructions apply to both Treatment and Prophylaxis</u></p><p><em>Dosage adjustment</em></p><p>For prophylaxis use, dose adjustments are not recommended in the case of lack of efficacy or treatment- related adverse events. In the case of treatment-related adverse events, discontinuation of voriconazole and use of alternative antifungal agents must be considered (see section 4.4 and 4.8)</p><p><em><u>Dosage adjustments in case of co-administration</u></em></p><p>Phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased from 200 mg to 400 mg orally, twice daily (100 mg to 200 mg orally, twice daily in patients less than 40 kg), see sections 4.4 and 4.5.</p><p>The combination of voriconazole with rifabutin should, if possible be avoided. However, if the combination is strictly needed, the maintenance dose of voriconazole may be increased from 200 mg to 350 mg orally, twice daily (100 mg to 200 mg orally, twice daily in patients less than 40 kg), see sections 4.4 and 4.5.</p><p>Efavirenz may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 400 mg every 12 hours and the efavirenz dose is reduced by 50%, i.e. to 300 mg once daily. When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored (see sections 4.4 and 4.5).</p><p><em>&nbsp;</em></p><p><em><u>Elderly patients</u></em></p><p>No dose adjustment is necessary for elderly patients (see section 5.2).</p><p><em>&nbsp;</em></p><p><em><u>Patients with renal impairment</u></em></p><p>The pharmacokinetics of orally administered voriconazole are not affected by renal impairment. Therefore, no adjustment is necessary for oral dosing for patients with mild to severe renal impairment (see section 5.2).</p><p>&nbsp;</p><p>Voriconazole is haemodialysed with a clearance of 121 ml/min. A four hour haemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.</p><p><em>&nbsp;</em></p><p><em><u>Patients with hepatic impairment</u></em></p><p>It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B) receiving voriconazole (see section 5.2).</p><p>&nbsp;</p><p>Voriconazole has not been studied in patients with severe chronic hepatic cirrhosis (Child-Pugh C).</p><p>&nbsp;</p><p>There is limited data on the safety of voriconazole in patients with abnormal liver function tests (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], or total bilirubin &gt;5 times the upper limit of normal).</p><p>&nbsp;</p><p>Voriconazole has been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice, and must only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk. Patients with severe hepatic impairment must be carefully monitored for drug toxicity (see section4.8).</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of voriconazole in children below 2 years has not been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Vultera film-coated tablets are to be taken at least one hour before, or one hour following, a meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

Coadministration with CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide or quinidine since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes (see section 4.5).

Coadministration with rifampicin, carbamazepine and phenobarbital since these medicinal products are likely to decrease plasma voriconazole concentrations significantly (see section 4.5).

Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg once daily or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations (see section 4.5, for lower doses see section 4.4).

Coadministration with high dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose (see section 4.5, for lower doses see section 4.4).

Coadministration with ergot alkaloids (ergotamine, dihydroergotamine), which are CYP3A4 substrates, since increased plasma concentrations of these medicinal products can lead to ergotism (see section 4.5).

Coadministration with sirolimus since voriconazole is likely to increase plasma concentrations of sirolimus significantly (see section 4.5).

Coadministration with St John’s Wort (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>Caution should be used in prescribing voriconazole to patients with hypersensitivity to other azoles (see also section 4.8).</p><p>&nbsp;</p><p><u>Cardiovascular</u></p><p>Voriconazole has been associated with QTc interval prolongation. There have been rare cases of torsades de pointes in patients taking voriconazole who had risk factors, such as history of cardiotoxic chemotherapy, cardiomyopathy, hypokalaemia and concomitant medicinal products that may have been contributory.</p><p>Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital or acquired QTc-prolongation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy, in particular when heart failure is present</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Existing symptomatic arrhythmias</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant medicinal product that is known to prolong QTc interval. Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.2). A study has been conducted in healthy volunteers which examined the effect on QTc interval of single doses of voriconazole up to 4 times the usual daily dose. No subject experienced an interval exceeding the potentially clinically relevant threshold of 500 msec (see section 5.1).</p><p>&nbsp;</p><p><u>Hepatic toxicity</u></p><p>In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with voriconazole (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly haematological malignancy).Transient hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy (see section 4.8).</p><p>&nbsp;</p><p><u>Monitoring of hepatic function</u></p><p>Patients receiving voriconazole must be carefully monitored for hepatic toxicity. Clinical management should include laboratory evaluation of hepatic function (specifically AST and ALT) at the initiation of treatment with voriconazole and at least weekly for the first month of treatment. Treatment duration should be as short as possible, however, if based on the benefit-risk assessment the treatment is continued (see section 4.2), monitoring frequency can be reduced to monthly if there are no changes in the liver function tests.</p><p>&nbsp;</p><p>If the liver function tests become markedly elevated, voriconazole should be discontinued, unless the medical judgment of the risk- benefit of the treatment for the patient justifies continued use.</p><p>&nbsp;</p><p>Monitoring of hepatic function should be carried out in both children and adults.</p><p>&nbsp;</p><p><u>Visual adverse reactions</u></p><p>There have been reports of prolonged visual adverse reactions, including blurred vision, optic neuritis and papilloedema (see section 4.8).</p><p>&nbsp;</p><p><u>Renal adverse reactions</u></p><p>Acute renal failure has been observed in severely ill patients undergoing treatment with voriconazole. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medicinal products and have concurrent conditions that may result in decreased renal function (see section 4.8).</p><p>&nbsp;</p><p><u>Monitoring of renal function</u></p><p>Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.</p><p>&nbsp;</p><p><u>Monitoring of pancreatic function</u></p><p>Patients, especially children, with risk factors for acute pancreatitis (e.g. recent chemotherapy,</p><p>haematopoietic stem cell transplantation (HSCT)), should be monitored closely during voriconazole treatment. Monitoring of serum amylase or lipase may be considered in this clinical situation.</p><p>&nbsp;</p><p><u>Dermatological adverse reactions</u></p><p>Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome, during treatment with voriconazole. If patients develop a rash they should be monitored closely and voriconazole discontinued if lesions progress.</p><p>&nbsp;</p><p>In addition voriconazole has been associated with phototoxicity and pseudoporphyria. It is recommended that all patients, including children, avoid exposure to direct sunlight during voriconazole treatment and use measures such as protective clothing and sunscreen with high sun protection factor (SPF).</p><p>&nbsp;</p><p><u>Long-term treatment</u></p><p>Long term exposure (treatment or prophylaxis) greater than 180 days (6 months) requires careful assessment of the benefit-risk balance and physicians should therefore consider the need to limit the exposure to voriconazole (see sections 4.2 and 5.1). The following severe adverse events have been reported in relation with long-term voriconazole treatment:</p><p>&nbsp;</p><p><u>Squamous cell carcinoma of the skin</u><u> (SCC)</u> has been reported in patients, some of whom have reported prior phototoxic reactions. If phototoxic reactions occur, multidisciplinary advice should be sought and the patient should be referred to a dermatologist. Voriconazole discontinuation and use of alternative antifungal agents should be considered. Dermatologic evaluation should be performed on a systematic and regular basis, whenever voriconazole is continued despite the occurrence of phototoxicity-related lesions, to allow early detection and management of premalignant lesions. Voriconazole should be discontinued if premalignant skin lesions or squamous cell carcinoma are identified.</p><p>&nbsp;</p><p><u>Non-infectious periostitis with elevated fluoride and alkaline phosphatase levels</u> has been reported in transplant patients. If a patient develops skeletal pain and radiologic findings compatible with periostitis voriconazole discontinuation should be considered after multidisciplinary advice.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Safety and effectiveness in paediatric subjects below the age of two years has not been established (see sections 4.8 and 5.1). Voriconazole is indicated for paediatric patients aged two years or older. Hepatic function should be monitored in both children and adults. Oral bioavailability may be limited in paediatric patients aged 2 to &lt;12 years with malabsorption and very low body weight for age. In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>The frequency of phototoxicity reactions is higher in the paediatric population. As an evolution towards SCC has been reported, stringent measures for the photoprotection are warranted in this population of patients. In children experiencing photoaging injuries such as lentigines or ephelides, sun avoidance and dermatologic follow-up are recommended even after treatment discontinuation.</p><p><u>&nbsp;</u></p><p><u>Prophylaxis</u></p><p>In case of treatment-related adverse events (hepatotoxicity, severe skin reactions including phototoxicity and SCC, severe or prolonged visual disorders and periostitis), discontinuation of voriconazole and use of alternative antifungal agents must be considered.</p><p>&nbsp;</p><p><u>Phenytoin (CYP2C9 substrate and potent CYP450 inducer)</u></p><p>Careful monitoring of phenytoin levels is recommended when phenytoin is coadministered with voriconazole. Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk (see section 4.5).</p><p>&nbsp;</p><p><u>Efavirenz (CYP450 inducer; CYP3A4 inhibitor and substrate)</u></p><p>When voriconazole is coadministered with efavirenz the dose of voriconazole should be increased to 400 mg every 12 hours and the dose of efavirenz should be decreased to 300 mg every 24 hours (see sections 4.2, 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Rifabutin (</u><u>Potent</u><u>CYP450 inducer)</u></p><p>Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g. uveitis) is recommended when rifabutin is coadministered with voriconazole. Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk (see section 4.5).</p><p>&nbsp;</p><p><u>Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate)</u></p><p>Coadministration of voriconazole and low dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see sections 4.5 and 4.3).</p><p>&nbsp;</p><p><u>Everolimus (CYP3A4 substrate, P-gp substrate)</u></p><p>Co-administration of voriconazole with everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations. Currently there are insufficient data to allow dosing recommendations in this situation (see section 4.5).</p><p>&nbsp;</p><p><u>Methadone (CYP3A4 substrate)</u></p><p>Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended when coadministered with voriconazole since methadone levels increased following co-administration of voriconazole. Dose reduction of methadone may be needed (see section 4.5).</p><p>&nbsp;</p><p><u>Short acting opiates (CYP3A4 substrate)</u></p><p>Reduction in the dose of alfentanil, fentanyl and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered when co-administered with voriconazole (see section 4.5). As the half-life of alfentanil is prolonged in a four-fold manner when alfentanil is coadministered with voriconazole and in an independent published study, concomitant use of voriconazole with fentanyl resulted in an increase in the mean AUC<sub>0-&infin;</sub> of fentanyl, frequent monitoring for opiate-associated adverse reactions (including a longer respiratory monitoring period) may be necessary.</p><p>&nbsp;</p><p><u>Long acting opiates (CYP3A4 substrate)</u></p><p>Reduction in the dose of oxycodone and other long-acting opiates metabolized by CYP3A4 (e.g., hydrocodone) should be considered when coadministered with voriconazole. Frequent monitoring for opiate-associated adverse reactions may be necessary (see section 4.5).</p><p>&nbsp;</p><p><u>Fluconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor)</u></p><p>Coadministration of oral voriconazole and oral fluconazole resulted in a significant increase in Cmax and AUC&tau; of voriconazole in healthy subjects. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole (see section 4.5).</p><p>&nbsp;</p><p>Vulteratablets contain lactose and should not be given to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voriconazole is metabolised by, and inhibits the activity of, cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively, and there is potential for voriconazole to increase the plasma concentrations of substances metabolised by these CYP450 isoenzymes.</p><p>Unless otherwise specified, drug interaction studies have been performed in healthy adult male subjects using multiple dosing to steady state with oral voriconazole at 200 mg twice daily (BID). These results are relevant to other populations and routes of administration.</p><p>&nbsp;</p><p>Voriconazole should be administered with caution in patients with concomitant medication that is known to prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide) co-administration is contraindicated (see below and section 4.3).</p><p>&nbsp;</p><p><u>Interaction table</u></p><p>Interactions between voriconazole and other medicinal products are listed in the table below (once daily as &ldquo;QD&rdquo;, twice daily as &ldquo;BID&rdquo;, three times daily as &ldquo;TID&rdquo; and not determined as &ldquo;ND&rdquo;). The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (&harr;), below (&darr;) or above (&uarr;) the 80-125% range. The asterisk (*) indicates a two way interaction. AUC&tau;, AUC<sub>t</sub> and AUC<sub>0-&infin;</sub>represent area under the curve over a dosing interval, from time zero to the time with detectable measurement and from time zero to infinity, respectively.</p><p>&nbsp;</p><p>The interactions in the table are presented in the following order: contraindications, those requiring dose adjustment and careful clinical and/or biological monitoring, and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning</strong></p><p><strong>co-administration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Astemizole, cisapride,</p><p>pimozide, quinidine and</p><p>terfenadine</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes.</p></td><td style="vertical-align:top"><p><strong>Contraindicated </strong>(seesection4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine and long-acting</p><p>barbiturates (e.g., phenobarbital,</p><p>mephobarbital)</p><p><em>[potent CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Although not studied,</p><p>carbamazepine and long-acting barbiturates are likely to significantly decrease plasma voriconazole concentrations.</p></td><td style="vertical-align:top"><p><strong>Contraindicated </strong>(see section4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz (a non-nucleoside</p><p>reverse transcriptase inhibitor) <em>[CYP450 inducer; CYP3A4inhibitor and substrate]</em></p><p><em>&nbsp;</em></p><p>Efavirenz 400 mg QD,</p><p>coadministered with voriconazole</p><p>200 mg BID*</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Efavirenz 300 mg QD, coadministered</p><p>withvoriconazole 400 mg BID*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Efavirenz Cmax &uarr; 38%</p><p>Efavirenz AUC&tau; &uarr; 44%</p><p>Voriconazole Cmax &darr; 61%</p><p>Voriconazole AUC&tau; &darr; 77%</p><p>&nbsp;</p><p>Compared to efavirenz 600 mg QD,</p><p>Efavirenz Cmax &harr;</p><p>Efavirenz AUC&tau; &uarr; 17%</p><p>&nbsp;</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax &uarr; 23%</p><p>Voriconazole AUC&tau;&darr;7%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Use of standard doses of</p><p>voriconazole with efavirenz doses of 400 mg QD or higher is <strong>contraindicated </strong>(see section 4.3).</p><p><strong>&nbsp;</strong></p><p>Voriconazole may be coadministered with efavirenz if the voriconazole maintenance dose is increased to 400 mg</p><p>BID and the efavirenz dose is decreased to 300 mg QD.</p><p>When voriconazole treatment is stopped, the initial dose of efavirenz should be restored (see section 4.2 and 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Ergot alkaloids (e.g.,</p><p>ergotamine and</p><p>dihydroergotamine)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma</p><p>concentrations of ergot alkaloids and lead to ergotism.</p></td><td style="vertical-align:top"><p><strong>Contraindicated </strong>(see section4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p><p><em>[potent CYP450 inducer]</em></p><p>&nbsp;</p><p>300 mg QD</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>300 mg QD (co-administered</p><p>with voriconazole 350 mg</p><p>BID)*</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>300 mg QD (co-administered</p><p>with voriconazole 400 mg</p><p>BID)*</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole Cmax &darr; 69%</p><p>Voriconazole AUC&tau; &darr; 78%</p><p>&nbsp;</p><p>&nbsp;</p><p>Compared to voriconazole 200 mg</p><p>BID,</p><p>Voriconazole Cmax &darr; 4%</p><p>Voriconazole AUC&tau; &darr; 32%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Rifabutin Cmax &uarr; 195%</p><p>Rifabutin AUC&tau; &uarr; 331%</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax &uarr; 104%</p><p>Voriconazole AUC&tau; &uarr; 87%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of</p><p>voriconazole and rifabutin should be avoided unless the benefit outweighs the risk.</p><p>The maintenance dose of voriconazole may be increased to 5 mg/kg intravenously BID or from 200 mg to 350 mg orally BID (100 mg to 200 mg orally BID in patients less than 40 kg) (see section 4.2).</p><p>Careful monitoring of full</p><p>blood counts and adverse</p><p>reactions to rifabutin (e.g.,</p><p>uveitis) is recommended when rifabutin is coadministered with voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin (600 mg QD)</p><p><em>[potent CYP450 inducer]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax &darr;93%</p><p>Voriconazole AUC&tau; &darr; 96%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Contraindicated </strong>(see section</p><p>4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir (protease inhibitor)</p><p><em>[potent CYP450 inducer;</em></p><p><em>CYP3A4 inhibitor and</em></p><p><em>substrate]</em></p><p>&nbsp;</p><p>High dose (400 mg BID)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Low dose (100 mg BID)*</p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ritonavir Cmax and AUC&tau;&harr;</p><p>Voriconazole Cmax &darr; 66%</p><p>Voriconazole AUC&tau; &darr; 82%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ritonavir Cmax &darr; 25%</p><p>Ritonavir AUC&tau; &darr;13%</p><p>Voriconazole Cmax &darr; 24%</p><p>Voriconazole AUC&tau; &darr; 39%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Co-administration of</p><p>voriconazole and high doses of ritonavir (400 mg and above BID) is<strong>contraindicated </strong>(see section 4.3).</p><p>&nbsp;</p><p>Co-administration of</p><p>voriconazole and low dose</p><p>ritonavir (100 mg BID) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>St John&rsquo;s Wort</p><p><em>[CYP450 inducer; P-gp</em></p><p><em>inducer]</em></p><p>300 mg TID (coadministered with voriconazole 400 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study, Voriconazole</p><p>AUC<sub>0-&infin;</sub> &darr; 59%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Contraindicated </strong>(see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Everolimus</p><p><em>[CYP3A4 substrate, P-gP</em></p><p><em>substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole</p><p>is likely to significantly increase the</p><p>plasma concentrations of</p><p>everolimus.</p></td><td style="vertical-align:top"><p>Co-administration of voriconazole with everolimus is not recommended because</p><p>voriconazole is expected to</p><p>significantly increase</p><p>everolimus concentrations (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole (200 mg QD)</p><p><em>[CYP2C9, CYP2C19 and</em></p><p><em>CYP3A4 inhibitor]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax &uarr; 57%</p><p>Voriconazole AUC&tau; &uarr; 79%</p><p>Fluconazole Cmax ND</p><p>Fluconazole AUC&tau;ND</p></td><td style="vertical-align:top"><p>The reduced dose and/or</p><p>frequency of voriconazole and fluconazole that would</p><p>eliminate this effect have not been established. Monitoring</p><p>for voriconazole-associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p><p><em>[CYP2C9 substrate and potent CYP450 inducer]</em></p><p>&nbsp;</p><p>300 mg QD</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>300 mg QD (co-administered</p><p>with voriconazole 400 mg</p><p>BID)*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole Cmax &darr; 49%</p><p>Voriconazole AUC&tau; &darr; 69%</p><p>&nbsp;</p><p>&nbsp;</p><p>Phenytoin Cmax &uarr; 67%</p><p>Phenytoin AUC&tau; &uarr; 81%</p><p>Compared to voriconazole 200 mg</p><p>BID,</p><p>Voriconazole Cmax &uarr; 34%</p><p>Voriconazole AUC&tau; &uarr; 39%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Concomitant use of</p><p>voriconazole and phenytoin</p><p>should be avoided unless the benefit outweighs the risk.</p><p>Careful monitoring of</p><p>phenytoin plasma levels is recommended.</p><p>&nbsp;</p><p>Phenytoin may be</p><p>co-administered with</p><p>voriconazole if the</p><p>maintenance dose of</p><p>voriconazole is increased to</p><p>5 mg/kg IV BID or from</p><p>200 mg to 400 mg oral BID,</p><p>(100 mg to 200 mg oral BID in patients less than 40 kg) (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulants</p><p>&nbsp;</p><p>Warfarin (30 mg single dose,</p><p>co- administered with 300 mg BID voriconazole)</p><p><em>[CYP2C9 substrate]</em></p><p>&nbsp;</p><p>Other oral coumarins</p><p>(e.g., phenprocoumon,</p><p>acenocoumarol)</p><p><em>[CYP2C9 and CYP3A4</em></p><p><em>substrates]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Maximum increase in prothrombin time was approximately 2-fold</p><p>&nbsp;</p><p>&nbsp;</p><p>Although not studied, voriconazole may increase the plasma concentrations of coumarins that may cause an increase in prothrombin time.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Close monitoring of</p><p>prothrombin time or other suitable anticoagulation tests is recommended, and the dose of anticoagulants should be adjusted accordingly.</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Benzodiazepines (e.g.,</p><p>midazolam, triazolam,</p><p>alprazolam)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied clinically, voriconazole is likely to increase the</p><p>plasma concentrations of</p><p>benzodiazepines that are</p><p>metabolised by CYP3A4 and lead to a prolonged sedative effect.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dose reduction of benzodiazepines should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressants</p><p><em>[CYP3A4 substrates]</em></p><p>&nbsp;</p><p>Sirolimus (2 mg single dose)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ciclosporin (In stable renal</p><p>transplant recipients receiving chronic ciclosporin therapy)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Tacrolimus (0.1 mg/kg single</p><p>dose)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Sirolimus Cmax &uarr; 6.6-fold</p><p>Sirolimus AUC<sub>0-&infin;</sub> &uarr; 11-fold</p><p>&nbsp;</p><p>Ciclosporin Cmax &uarr; 13%</p><p>Ciclosporin AUC&tau; &uarr; 70%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Tacrolimus Cmax &uarr; 117%</p><p>Tacrolimus AUCt &uarr; 221%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Co-administration of voriconazole and sirolimus is <strong>contraindicated </strong>(see section</p><p>4.3).</p><p>&nbsp;</p><p>When initiating voriconazole</p><p>in patients already on</p><p>ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored. Increased</p><p>ciclosporin levels have been</p><p>associated with nephrotoxicity.</p><p><u>When voriconazole is</u></p><p><u>discontinued, ciclosporin</u></p><p><u>levels must be carefully</u></p><p><u>monitored and the dose</u></p><p><u>increased as necessary.</u></p><p>&nbsp;</p><p>When initiating voriconazole</p><p>in patients already on tacrolimus, it is recommended that the tacrolimus dose be reduced to a third of the original dose and tacrolimus level carefully monitored.</p><p>Increased tacrolimus levels</p><p>have been associated with</p><p>nephrotoxicity. When</p><p>voriconazole is discontinued,</p><p>tacrolimus levels must be</p><p>carefully monitored and the dose increased as necessary.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Long Acting Opiates</p><p><em>[CYP3A4 substrates]</em></p><p>&nbsp;</p><p>Oxycodone (10 mg single</p><p>dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Oxycodone Cmax &uarr; 1.7-fold</p><p>Oxycodone AUC<sub>0-&infin;</sub> &uarr; 3.6-fold</p></td><td style="vertical-align:top"><p>Dose reduction in oxycodone</p><p>and other long-acting opiates</p><p>metabolized by CYP3A4</p><p>(e.g., hydrocodone) should be considered. Frequent</p><p>monitoring for opiate-associated adverse reactions may be necessary.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Methadone (32-100 mg QD)</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>R-methadone (active) Cmax &uarr; 31%</p><p>R-methadone (active) AUC&tau; &uarr; 47%</p><p>S-methadone Cmax &uarr; 65%</p><p>S-methadone AUC&tau; &uarr; 103%</p></td><td style="vertical-align:top"><p>Frequent monitoring for</p><p>adverse reactions and toxicity</p><p>related to methadone,</p><p>including QT prolongation, is recommended. Dose reduction of methadone may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Non-Steroidal Anti-</p><p>Inflammatory Drugs (NSAIDs)</p><p><em>[CYP2C9 substrates]</em></p><p>&nbsp;</p><p>Ibuprofen (400 mg single</p><p>dose)</p><p>&nbsp;</p><p>Diclofenac (50 mg single</p><p>dose)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>S-Ibuprofen Cmax &uarr; 20%</p><p>S-Ibuprofen AUC<sub>0-&infin;</sub> &uarr; 100%</p><p>&nbsp;</p><p>Diclofenac Cmax &uarr; 114%</p><p>Diclofenac AUC<sub>0-&infin;</sub> &uarr; 78%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Frequent monitoring for</p><p>adverse reactions and toxicity</p><p>related to NSAIDs is recommended. Dose reduction of NSAIDs may be needed.</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Omeprazole (40 mg QD)*</p><p><em>[CYP2C19 inhibitor; CYP2C19 and CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Omeprazole Cmax &uarr; 116%</p><p>Omeprazole AUC&tau; &uarr; 280%</p><p>Voriconazole Cmax &uarr; 15%</p><p>Voriconazole AUC&tau; &uarr; 41%</p><p>&nbsp;</p><p>Other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of these medicinal products.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>No dose adjustment of</p><p>voriconazole is recommended.</p><p>&nbsp;</p><p>When initiating voriconazole</p><p>in patients already receiving</p><p>omeprazole doses of 40 mg or above, it is recommended that the omeprazole dose be halved.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of Interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning</strong></p><p><strong>co-administration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Oral Contraceptives*</p><p><em>[CYP3A4 substrate; CYP2C19 inhibitor]</em></p><p>Norethisterone/ethinylestradiol</p><p>(1 mg/0.035 mg QD)</p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Ethinylestradiol Cmax &uarr; 36%</p><p>Ethinylestradiol AUC&tau; &uarr; 61%</p><p>Norethisterone Cmax &uarr; 15%</p><p>Norethisterone AUC&tau; &uarr; 53%</p><p>Voriconazole Cmax &uarr; 14%</p><p>Voriconazole AUC&tau; &uarr; 46%</p></td><td style="vertical-align:top"><p>Monitoring for adverse</p><p>reactions related to oral</p><p>contraceptives, in addition to</p><p>those for voriconazole, is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Short Acting Opiates</p><p><em>[CYP3A4 substrates]</em></p><p>&nbsp;</p><p>Alfentanil (20 &mu;g/kg single</p><p>dose, with concomitant</p><p>naloxone)</p><p>&nbsp;</p><p>Fentanyl (5 &mu;g/kg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Alfentanil AUC<sub>0-&infin;</sub> &uarr; 6-fold</p><p>&nbsp;</p><p>In an independent published study,</p><p>Fentanyl AUC<sub>0-&infin;</sub> &uarr; 1.34-fold</p></td><td style="vertical-align:top"><p>Dose reduction of alfentanil,</p><p>fentanyl and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered.</p><p>Extended and frequent</p><p>monitoring for respiratory depression and other opiate-associated adverse reactions is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Statins (e.g., lovastatin)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied clinically, voriconazole is likely to increase the plasma concentrations of statins that</p><p>are metabolised by CYP3A4 and could lead to rhabdomyolysis.</p></td><td style="vertical-align:top"><p>Dose reduction of statins should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Sulphonylureas (e.g.,</p><p>tolbutamide, glipizide,</p><p>glyburide)</p><p><em>[CYP2C9 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of sulphonylureas and cause hypoglycaemia.</p></td><td style="vertical-align:top"><p>Careful monitoring of blood glucose is recommended. Dose reduction of sulfonylureas should be considered.</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vinca Alkaloids (e.g.,</p><p>vincristine and vinblastine)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of vinca alkaloids and lead to neurotoxicity.</p></td><td style="vertical-align:top"><p>Dose reduction of vinca alkaloids should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Other HIV Protease Inhibitors</p><p>(e.g., saquinavir, amprenavir</p><p>and nelfinavir)*</p><p><em>[CYP3A4 substrates and</em></p><p><em>inhibitors]</em></p></td><td style="vertical-align:top"><p>Not studied clinically. <em>In vitro </em>studies show that voriconazole mayinhibit the metabolism of HIV protease inhibitors and the metabolism of voriconazole may also be inhibited by HIV protease inhibitors.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Careful monitoring for any</p><p>occurrence of drug toxicity</p><p>and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of Interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning</strong></p><p><strong>co-administration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Other Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (e.g., delavirdine, nevirapine)*</p><p><em>[CYP3A4 substrates, inhibitors or CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Not studied clinically. <em>In vitro </em>studies show that the metabolism ofvoriconazole may be inhibited byNNRTIs and voriconazole mayinhibit the metabolism of NNRTIs.The findings of the effect ofefavirenz on voriconazole suggest<em> </em>that the metabolism of voriconazole may be induced by a NNRTI.</p></td><td style="vertical-align:top"><p>Careful monitoring for any</p><p>occurrence of drug toxicity</p><p>and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine (400 mg BID)</p><p><em>[non-specific CYP450 inhibitor and increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax &uarr; 18%</p><p>Voriconazole AUC&tau; &uarr; 23%</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin (0.25 mg QD)</p><p><em>[P-gp substrate]</em></p></td><td style="vertical-align:top"><p>Digoxin Cmax &harr;</p><p>Digoxin AUC&tau;&harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir (800 mg TID)</p><p><em>[CYP3A4 inhibitor and</em></p><p><em>substrate]</em></p></td><td style="vertical-align:top"><p>Indinavir Cmax &harr;</p><p>Indinavir AUC&tau;&harr; Voriconazole Cmax &harr;</p><p>Voriconazole AUC&tau;&harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Macrolide antibiotics</p><p>&nbsp;</p><p>Erythromycin (1 g BID)</p><p><em>[CYP3A4 inhibitor]</em></p><p>&nbsp;</p><p>Azithromycin (500 mg QD)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole Cmax and AUC&tau;&harr;</p><p>&nbsp;</p><p>Voriconazole Cmax and AUC&tau;&harr;</p><p>&nbsp;</p><p>The effect of voriconazole on either erythromycin or azithromycin is unknown.</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Mycophenolic acid (1 g single</p><p>dose)</p><p><em>[UDP-glucuronyl transferase</em></p><p><em>substrate]</em></p></td><td style="vertical-align:top"><p>Mycophenolic acid Cmax &harr;</p><p>Mycophenolic acid AUCt &harr;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Prednisolone (60 mg single</p><p>dose)</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Prednisolone Cmax &uarr; 11%</p><p>Prednisolone AUC<sub>0-&infin;</sub> &uarr; 34%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Ranitidine (150 mg BID)<em> [increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax and AUC&tau;&harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data on the use of voriconazole in pregnant women available.</p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p>Voriconazole must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Women of child-bearing potential</u></p><p>Women of child-bearing potential must always use effective contraception during treatment.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>The excretion of voriconazole into breast milk has not been investigated. Breast-feeding must be stopped on initiation of treatment with voriconazole.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In an animal study, no impairment of fertility was demonstrated in male and female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voriconazole has moderate influence on the ability to drive and use machines. It may cause transient and reversible changes to vision, including blurring, altered/enhanced visual perception and/or photophobia. Patients must avoid potentially hazardous tasks, such as driving or operating machinery while experiencing these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>The safety profile of voriconazole is based on an integrated safety database of more than 2,000 subjects (including 1,655 patients in therapeutic trials and 279 in prophylaxis trials). This represents a heterogeneous population, containing patients with haematological malignancy, HIV infected patients with oesophageal candidiasis and refractory fungal infections, non-neutropenic patients with candidaemia or aspergillosis and healthy volunteers. Seven hundred and five (705) patients had a duration of voriconazole therapy of greater than 12 weeks, with 164 patients receiving voriconazole for over 6 months.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions were visual disturbances, pyrexia, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema, liver function test abnormal, respiratory distress and abdominal pain.</p><p>&nbsp;</p><p>The severity of the adverse reactions was generally mild to moderate. No clinically significant differences were seen when the safety data were analysed by age, race, or gender.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>In the table below, since the majority of the studies were of an open nature all causality adverse reactions, by system organ class and frequency, are listed.</p><p>&nbsp;</p><p>Frequency categories are expressed as: Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Undesirable effects reported in subjects receiving voriconazole:</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse drug reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gastroenteritis, sinusitis, gingivitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pseudomembranous colitis, lymphangitis, peritonitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neoplasms Benign, Malignant and Unspecified (including cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Squamous cell carcinoma*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pancytopenia, agranulocytosis,thrombocytopenia, anaemia,</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Disseminated intravascular coagulation,</p><p>bone marrow failure,leukopenia, lymphadenopathy, eosinophilia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anaphylactoid reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Adrenal insufficiency, hypothyroidism</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hyperthyroidism</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Oedema peripheral</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypoglycaemia, hypokalaemia,hyponatremia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Depression, hallucination, anxiety, insomnia, agitation, confusional state</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Convulsion,&nbsp; tremor, paraesthesia, hypertonia, somnolence, syncope, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Brain oedema, encephalopathy, extrapyramidal disorder, neuropathy peripheral, ataxia, hypoaesthesia, dysgeusia, nystagmus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatic encephalopathy, Guillain-Barresyndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Visual impairment(including blurred vision [see section 4.4]chromatopsia and photophobia)</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Retinal haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oculogyric crisis,Papilloedema (see section 4.4), optic nerve disorder (including optic neuritis, see section 4.4), scleritis, blepharitis, diplopia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Optic atrophy, corneal opacity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypoacusis, vertigo, tinnitus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arrhythmia supraventricular, tachycardia, bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Ventricular fibrillation, ventricular extrasystoles,supraventricular tachycardia, ventriculartachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Torsades de pointes,</p><p>atrioventricular block complete, bundle branch block, nodal rhythm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension, phlebitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombophlebitis,</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Respiratory distress</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome, pulmonary oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Abdominal pain, nausea, vomiting, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspepsia, constipation, cheilitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancreatitis, duodenitis, glossitis, swollen tongue,</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Liver function test abnormal(including AST, ALT, alkaline phosphatase, gamma-glutamyltranspeptidase [GGT], lactate dehydrogenase [LDH], bilirubin), cholecystitis</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Jaundice, cholestatic jaundice,hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatic failure, hepatomegaly, cholecystitis, cholelithiasis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Exfoliative dermatitis, maculo-papular rash, pruritus, alopecia, erythema</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, Erythema multiforme, angioedema, allergic dermatitis, urticaria, psoriasis, phototoxicity, rash macular, rash papular, purpura, eczema</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pseudoporphyria, fixed drug eruption</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Cutaneous lupus erythematosis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Arthritis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Periostitis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal failure acute, haematuria</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Renal tubular necrosis, proteinuria, nephritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Chest pain, face oedema, chills,</p><p>Asthenia, influenza like illness,</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Injection site reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Electrocardiogram QTc prolonged, blood urea increased, blood cholesterol increased</p></td></tr></tbody></table><p>*Undesirable events identified during post-approval use</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>&nbsp;</em></p><p><em>Visual disturbances</em></p><p>In clinical trials, visual impairments with voriconazole were very common. In therapeutic studies, voriconazole treatment-related visual disturbances were very common. In these studies, short-term as well as long-term treatment, approximately 21 % of subjects experienced altered/enhanced visual perception, blurred vision, colour vision change or photophobia. These visual disturbances were transient and fully reversible, with the majority spontaneously resolving within 60 minutes and no clinically significant long-term visual effects were observed. There was evidence of attenuation with repeated doses of voriconazole. The visual disturbances were generally mild, rarely resulted in discontinuation and were not associated with long-term sequelae. Visual disturbances may be associated with higher plasma concentrations and/or doses.</p><p>&nbsp;</p><p>The mechanism of action is unknown, although the site of action is most likely to be within the retina. In a study in healthy volunteers investigating the impact of voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude. The ERG measures electrical currents in the retina. The ERG changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.</p><p><em>&nbsp;</em></p><p>There have been post-marketing reports of prolonged visual adverse events (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Dermatological reactions</em></p><p>Dermatological reactions were common in patients treated with voriconazole in clinical trials, but these patients had serious underlying diseases and were receiving multiple concomitant medicinal products. The majority of rashes were of mild to moderate severity. Patients have rarely developed serious cutaneous reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme during treatment with voriconazole.</p><p>&nbsp;</p><p>If patients develop a rash they should be monitored closely and voriconazole discontinued if lesions progress.</p><p>Photosensitivity reactions have been reported, especially during long-term therapy (see section 4.4).</p><p>&nbsp;</p><p>There have been reports of squamous cell carcinoma of the skin in patients treated with voriconazole for long periods of time; the mechanism has not been established (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Liver function tests</em></p><p>The overall incidence of clinically significant transaminase abnormalities in the voriconazole clinical programme was 13. 5 % (258/1918) of subjects treated with voriconazole. Liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.</p><p>&nbsp;</p><p>Voriconazole has been infrequently associated with cases of serious hepatic toxicity in patients with other serious underlying conditions. This includes cases of jaundice, and rare cases of hepatitis and hepatic failure leading to death (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Prophylaxis</em></p><p>In an open-label, comparative, multicenter study comparing voriconazole and itraconazole as primary prophylaxis in adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI, permanent discontinuation of voriconazole due to AEs was reported in 39.3% of subjects versus 39.6% of subjects in the itraconazole arm. Treatment-emergent hepatic AEs resulted in permanent discontinuation of study medication for 50 subjects (21.4%) treated with voriconazole and for 18 subjects (7.1%) treated with itraconazole.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety of voriconazole was investigated in 285 paediatric patients aged 2 to &lt;12 years who were treated with voriconazole in pharmacokinetic studies (127 paediatric patients) and in compassionate use programs (158 paediatric patients). The adverse reaction profile of these 285 paediatric patients was similar to that in adults. Post-marketing data suggest there might be a higher occurrence of skin reactions (especially erythema) in the paediatric population compared to adults. In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse reactions (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1), blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1). There have been post-marketing reports of pancreatitis in paediatric patients.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials there were 3 cases of accidental overdose. All occurred in paediatric patients, who received up to five times the recommended intravenous dose of voriconazole. A single adverse reaction of photophobia of 10 minutes duration was reported.</p><p>&nbsp;</p><p>There is no known antidote to voriconazole.</p><p>&nbsp;</p><p>Voriconazole is haemodialysed with a clearance of 121 ml/min. In an overdose, haemodialysis may assist in the removal of voriconazole from the body.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC: J02AC03</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.</p><p>&nbsp;</p><p><u>Pharmacokinetic/Pharmacodynamic Relationship</u></p><p>In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742 ng/ml (interquartile range 2027 to 6302 ng/ml), respectively. A positive association between mean, maximum or minimum plasma voriconazole concentration and efficacy in therapeutic studies was not found and this relationship has not been explored in prophylaxis studies.</p><p>&nbsp;</p><p>Pharmacokinetic-Pharmacodynamic analyses of clinical trial data identified positive associations between plasma voriconazole concentrations and both liver function test abnormalities and visual disturbances. Dose adjustments in prophylaxis studies have not been explored.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>I<em>n vitro</em>, voriconazole displays broad-spectrum antifungal activity with antifungal potency against <em>Candida </em>species (including fluconazole resistant <em>C. krusei </em>and resistant strains of <em>C. glabrata </em>and <em>C. albicans</em>) and fungicidal activity against all <em>Aspergillus </em>species tested. In addition voriconazole shows <em>invitro </em>fungicidal activity against emerging fungal pathogens, including those such as <em>Scedosporium </em>or <em>Fusarium </em>which have limited susceptibility to existing antifungal agents.</p><p>&nbsp;</p><p>Clinical efficacy defined as partial or complete response has been demonstrated for <em>Aspergillus </em>spp. including <em>A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans,Candida </em>spp.<em>, </em>including <em>C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis </em>and limited numbers of <em>C. dubliniensis, C. inconspicua, </em>and <em>C. guilliermondii, Scedosporium </em>spp., including <em>S.apiospermum, S. prolificans and Fusarium </em>spp.</p><p>&nbsp;</p><p>Other treated fungal infections (oftenwith either partial or complete response) included isolated cases of <em>Alternaria </em>spp., <em>Blastomyces dermatitidis, Blastoschizomyces capitatus, Cladosporium </em>spp<em>., Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, Penicillium spp. including P. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis and Trichosporon </em>spp. including <em>T. beigelii </em>infections.</p><p><em>&nbsp;</em></p><p><em>In vitro </em>activity against clinical isolates has been observed for <em>Acremonium </em>spp., <em>Alternaria </em>spp., <em>Bipolaris </em>spp<em>., Cladophialophora </em>spp. and<em> Histoplasma capsulatum, </em>with most strains being inhibited by concentrationsof voriconazole in the range 0.05 to 2 &mu;g/ml.</p><p><em>&nbsp;</em></p><p><em>In vitro </em>activity against the following pathogens has been shown, but the clinical significance is unknown: <em>Curvularia </em>spp. and <em>Sporothrix </em>spp.</p><p>&nbsp;</p><p>Breakpoints</p><p>&nbsp;</p><p>Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</p><p>&nbsp;</p><p>The species most frequently involved in causing human infections include <em>C. albicans, C. parapsilosis, C. tropicalis, C. glabrata </em>and <em>C. krusei</em>, all of which usually exhibit minimal inhibitory concentration (MICs) of less than 1 mg/L for voriconazole.</p><p>&nbsp;</p><p>However, the <em>in vitro </em>activity of voriconazole against <em>Candida </em>species is not uniform. Specifically, for <em>C. glabrata, </em>the MICs of voriconazole for fluconazole-resistant isolates are proportionally higher than are thoseof fluconazole-susceptible isolates. Therefore, every attempt should be made to identify <em>Candida </em>to specieslevel. If antifungal susceptibility testing is available, the MIC results may be interpreted using breakpointcriteria established by European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>EUCAST Breakpoints</u></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Candida Species</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MIC breakpoint (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&le;S (Susceptible)</strong></p></td><td style="vertical-align:top"><p><strong>&gt;R (Resistant)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Candida albicans<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida tropicalis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida glabrata<sup>2</sup></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei<sup>3</sup></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td style="vertical-align:top"><p><em>Other Candida spp.<sup>4</sup></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><sup>1</sup></strong>Strains with MIC values above the Susceptible (S) breakpoint are rare, or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory.</p><p><strong><sup>2</sup></strong>In clinical studies, response to voriconazole in patients with <em>C glabrata </em>infections was 21% lower compared to <em>C. albicans, C. parapsilosis and C. tropicalis. </em>However, this reduced response was not correlated withelevated MICs.</p><p><strong><sup>3</sup></strong>In clinical studies, response to voriconazole in <em>C. krusei </em>infections was similar to <em>C. albicans, C. parapsilosis and C. tropicalis. </em>However, as there were only 9 cases available for EUCAST analysis, there is currently insufficient evidence to set clinical breakpoints for <em>C. krusei</em>.</p><p><strong><sup>4</sup></strong>EUCAST has not determined non-species related breakpoints for</p><p>voriconazole.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Clinical Experience</u></p><p>Successful outcome in this section is defined as complete or partial response.</p><p><em>&nbsp;</em></p><p><em><u>Aspergillus </u></em><u>infections &ndash; efficacy in aspergillosis patients with poor prognosis</u></p><p>Voriconazole has <em>in vitro </em>fungicidal activity against <em>Aspergillus </em>spp. The efficacy and survival benefit of voriconazole versusconventional amphotericin B in the primary treatment of acute invasive aspergillosis was demonstrated in anopen, randomised, multicentre study in 277 immunocompromised patients treated for 12 weeks.Voriconazole was administered intravenously with a loading dose of 6 mg/kg every 12 hours for the first 24hours followed by a maintenance dose of 4 mg/kg every 12 hours for a minimum of seven days. Therapycould then be switched to the oral formulation at a dose of 200 mg every 12 hours. Median duration of IVvoriconazole therapy was 10 days (range 2-85 days). After IV voriconazole therapy, the median duration oforal voriconazole therapy was 76 days (range 2-232 days).</p><p>&nbsp;</p><p>A satisfactory global response (complete or partial resolution of all attributable symptoms signs, radiographic/bronchoscopic abnormalities present at baseline) was seen in 53 % of voriconazole-treated patients compared to 31 % of patients treated with comparator. The 84-day survival rate for voriconazole was statistically significantly higher than that for the comparator and a clinically and statistically significant benefit was shown in favour of voriconazole for both time to death and time to discontinuation due to toxicity.</p><p>&nbsp;</p><p>This study confirmed findings from an earlier, prospectively designed study where there was a positive outcome in subjects with risk factors for a poor prognosis, including graft versus host disease, and, in particular, cerebral infections (normally associated with almost 100 % mortality).</p><p>&nbsp;</p><p>The studies included cerebral, sinus, pulmonary and disseminated aspergillosis in patients with bone marrow and solid organ transplants, haematological malignancies, cancer and AIDS.</p><p>&nbsp;</p><p><u>Candidaemia in non-neutropenic patients</u></p><p>The efficacy of voriconazole compared to the regimen of amphotericin B followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study. Three hundred and seventy non-neutropenic patients (above 12 years of age) with documented candidaemia were included in the study, of whom 248 were treated with voriconazole. Nine subjects in the voriconazole group and five in the amphotericin B followed by fluconazole group also had mycologically proven infection in deep tissue. Patients with renal failure were excluded from this study. The median treatment duration was 15 days in both treatment arms. In the primary analysis, successful response as assessed by a Data Review Committee (DRC) blinded to study medicinal product was defined as resolution/improvement in all clinical signs and symptoms of infection with eradication of <em>Candida </em>from blood and infected deep tissue sites 12 weeks after the end of therapy (EOT). Patients who did not have an assessment 12 weeks after EOT were counted as failures. In this analysis a successful response was seen in 41 % of patients in both treatment arms.</p><p>&nbsp;</p><p>In a secondary analysis, which utilised <em>DRC </em>assessments at the latest evaluable time point (EOT, or 2, 6, or 12 weeks after EOT) voriconazole and the regimen of amphotericin B followed by fluconazole had successful response rates of 65 % and 71 %, respectively.</p><p>The Investigator&rsquo;s assessment of successful outcome at each of these time points is shown in the following table.</p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Timepoint</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Voriconazole</em></strong></p><p><strong><em>(N=248)</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Amphotericin B</em></strong></p><p><strong><em>&rarr; fluconazole</em></strong></p><p><strong><em>(N=122)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>EOT</em></strong></p></td><td style="vertical-align:top"><p><strong><em>178 (72 %)</em></strong></p></td><td style="vertical-align:top"><p><strong><em>88 (72 %)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>2 weeks after</em></strong></p><p><strong><em>EOT</em></strong></p></td><td style="vertical-align:top"><p><strong><em>125 (50 %)</em></strong></p></td><td style="vertical-align:top"><p><strong><em>62 (51 %)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>6 weeks after</em></strong></p><p><strong><em>EOT</em></strong></p></td><td style="vertical-align:top"><p><strong><em>104 (42 %)</em></strong></p></td><td style="vertical-align:top"><p><strong><em>55 (45 %)</em></strong></p><p><strong><em>&nbsp;</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>12 weeks after</em></strong></p><p><strong><em>EOT</em></strong></p></td><td style="vertical-align:top"><p><strong><em>104 (42 %)</em></strong></p></td><td style="vertical-align:top"><p><strong><em>51 (42 %)</em></strong></p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p><u>Serious refractory <em>Candida </em>infections</u></p><p>The study comprised 55 patients with serious refractory systemic <em>Candida </em>infections (including candidaemia, disseminated and other invasive candidiasis) where prior antifungal treatment, particularly with fluconazole, had been ineffective. Successful response was seen in 24 patients (15 complete, 9 partial responses). In fluconazole-resistant non <em>albicans </em>species, a successful outcome was seen in 3/3 <em>C. krusei</em> (complete responses) and 6/8 <em>C. glabrata </em>(5 complete, 1 partial response) infections. The clinical efficacy data were supported by limited susceptibility data.</p><p>&nbsp;</p><p><em><u>Scedosporium </u></em><u>and <em>Fusarium </em>infections</u></p><p>Voriconazole was shown to be effective against the following rare fungal pathogens:</p><p><em>&nbsp;</em></p><p><em>Scedosporium </em>spp.: Successful response to voriconazole therapy was seen in 16 (6 complete, 10 partial responses) of 28 patients with <em>S. apiospermum </em>and in 2 (both partial responses) of 7 patients with <em>S.prolificans </em>infection. In addition, a successful response was seen in 1 of 3 patients with infections caused by more than one organism including <em>Scedosporium </em>spp.</p><p><em>&nbsp;</em></p><p><em>Fusarium </em>spp.: Seven (3 complete, 4 partial responses) of 17 patients were successfully treated with voriconazole. Of these 7 patients, 3 had eye, 1 had sinus, and 3 had disseminated infection. Four additional patients with fusariosis had an infection caused by several organisms; two of them had a successful outcome.</p><p>&nbsp;</p><p>The majority of patients receiving voriconazole treatment of the above mentioned rare infections were intolerant of, or refractory to, prior antifungal therapy.</p><p><u>&nbsp;</u></p><p><u>Primary Prophylaxis of Invasive Fungal Infections - Efficacy in HSCT recipients without prior proven orprobable IFI</u></p><p>Voriconazole was compared to itraconazole as primary prophylaxis in an open-label, comparative, multicenter study of adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI. Success was defined as the ability to continue study drug prophylaxis for 100 days after HSCT (without stopping for &gt;14 days) and survival with no proven or probable IFI for 180 days after HSCT. The modified intent-to-treat (MITT) group included 465 allogeneic HSCT recipients with 45% of patients having AML. From all patients 58% were subject to myeloablative conditions regimens. Prophylaxis with study drug was started immediately after HSCT: 224 received voriconazole and 241 received itraconazole. The median duration of study drug prophylaxis was 96 days for voriconazole and 68 days for itraconazole in the MITT group.</p><p>&nbsp;</p><p>Success rates and other secondary endpoints are presented in the table below:</p><table border="1" cellspacing="1" cellpadding="1" style="width:824px"><tbody><tr><td style="width:180px">Study Endpoints</td><td style="width:144px"><p>Voriconazole</p><p>N=224</p></td><td style="width:143px"><p>Itraconazole</p><p>N=241</p></td><td style="width:165px">Difference in proportions and the 95% confidence interval (CI)</td><td style="width:189px">P-Value</td></tr><tr><td style="width:180px">Success at day 180*</td><td style="width:144px">109 (48.7%)</td><td style="width:143px">80 (33.2%)</td><td style="width:165px">16.4% (7.7%, 25.1%)**</td><td style="width:189px">0.0002**</td></tr><tr><td style="width:180px">Success at day 100</td><td style="width:144px">121 (54.0%)</td><td style="width:143px">96 (39.8%)</td><td style="width:165px">15.4% (6.6%, 24.2%)**</td><td style="width:189px">0.0006**</td></tr><tr><td style="width:180px">Completed at least 100 days of study drug prophylaxis</td><td style="width:144px">120 (53.6%)</td><td style="width:143px">94 (39.0%)</td><td style="width:165px">14.6% (5.6%, 23.5%)</td><td style="width:189px">0.0015</td></tr><tr><td style="width:180px">Survived to day 180</td><td style="width:144px">184 (82.1%)</td><td style="width:143px">197 (81.7%)</td><td style="width:165px">0.4% (-6.6%, 7.4%)</td><td style="width:189px">0.9107</td></tr><tr><td style="width:180px">Developed proven or probable IFI to day 180</td><td style="width:144px">3 (1.3%)</td><td style="width:143px">5 (2.1%)</td><td style="width:165px">-0.7% (-3.1%, 1.6%)</td><td style="width:189px">0.5390</td></tr><tr><td style="width:180px">Developed proven or probable IFI to day 100</td><td style="width:144px">2 (0.9%)</td><td style="width:143px">4 (1.7%)</td><td style="width:165px">-0.8% (-2.8%, 1.3%)</td><td style="width:189px">0.4589</td></tr><tr><td style="width:180px">Developed proven or probable IFI while on study drug</td><td style="width:144px">0</td><td style="width:143px">3 (1.2%)</td><td style="width:165px">-1.2% (-2.6%, 0.2%)</td><td style="width:189px">0.0813</td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0" style="width:649px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Primary endpoint of the study</p><p>** Difference in proportions, 95% CI and p-valuesobtained after adjustment for randomization</p><p>&nbsp;</p><p>The breakthrough IFI rate to Day 180 and the primary endpoint of the study, which is Success at Day 180, for patients with AML and myeloablative conditioning regimens respectively, is presented in the table below:</p><p>AML</p><table border="1" cellspacing="1" cellpadding="1" style="width:775px"><tbody><tr><td style="width:187px">Study endpoints</td><td style="width:157px"><p>Voriconazole</p><p>(N=98)</p></td><td style="width:204px"><p>Itraconazole</p><p>(N=109)</p></td><td style="width:226px">Difference in proportions and the 95% confidence interval (CI)</td></tr><tr><td style="width:187px">Breakthrough IFI - Day 180</td><td style="width:157px">1 (1.0%)</td><td style="width:204px">2 (1.8%)</td><td style="width:226px">-0.8% (-4.0%, 2.4%) **</td></tr><tr><td style="width:187px">Success at Day 180*</td><td style="width:157px">55 (56.1%)</td><td style="width:204px">45 (41.3%)</td><td style="width:226px">14.7% (1.7%, 27.7%)***</td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0" style="width:231px"><tbody><tr><td style="vertical-align:top; width:97px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:14px"><p>&nbsp;</p></td></tr></tbody></table><p>* Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>***Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p>Myeloablative conditioning regimens</p><table border="1" cellspacing="1" cellpadding="1" style="width:810px"><tbody><tr><td style="width:184px">Study endpoints</td><td style="width:194px"><p>Voriconazole</p><p>(N=125)</p></td><td style="width:177px"><p>Itraconazole</p><p>(N=143)</p></td><td style="width:252px">Difference in proportions and the 95% confidence interval (CI)</td></tr><tr><td style="width:184px">Breakthrough IFI - Day 180</td><td style="width:194px">2 (1.6%)</td><td style="width:177px">3 (2.1%)</td><td style="width:252px">-0.5% (-3.7%, 2.7%) **</td></tr><tr><td style="width:184px">Success at Day 180*</td><td style="width:194px">70 (56.0%)</td><td style="width:177px">53 (37.1%)</td><td style="width:252px">20.1% (8.5%, 31.7%)***</td></tr></tbody></table><p>* Primary endpoint of study</p><p><span style="text-align:unset">** Using a margin of 5%, non inferiority is demonstrated</span>* Primary endpoint of study</p><p>*** Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p><u>Secondary Prophylaxis of IFI - Efficacy in HSCT recipients with prior proven or probable IFI</u> Voriconazole was investigated as secondary prophylaxis in an open-label, non-comparative, multicenter study of adult allogeneic HSCT recipients with prior proven or probable IFI. The primary endpoint was the rate of occurrence of proven and probable IFI during the first year after HSCT. The MITT group included 40 patients with prior IFI, including 31 with aspergillosis, 5 with candidiasis, and 4 with other IFI. The median duration of study drug prophylaxis was 95.5 days in the MITT group.</p><p>&nbsp;</p><p>Proven or probable IFIs developed in 7.5% (3/40) of patients during the first year after HSCT, including one candidemia, one scedosporiosis (both relapses of prior IFI), and one zygomycosis. The survival rate at Day 180 was 80.0% (32/40) and at 1 year was 70.0% (28/40).</p><p>&nbsp;</p><p><u>Duration of treatment</u></p><p>In clinical trials, 705 patients received voriconazole therapy for greater than 12 weeks, with 164 patients receiving voriconazole for over 6 months.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Sixty one paediatric patients aged 9 months up to 15 years who had definite or probable invasive fungal infections, were treated with voriconazole. This population included 34 patients 2 to &lt;12 years old and 20 patients 12-15 years of age.</p><p>&nbsp;</p><p>The majority (57/61) had failed previous antifungal therapies. Therapeutic studies included 5 patients aged 12-15 years, the remaining patients received voriconazole in the compassionate use programmes. Underlying diseases in these patients included haematological malignancies (27 patients) and chronic granulomatous disease (14 patients). The most commonly treated fungal infection was aspergillosis (43/61; 70 %).</p><p>&nbsp;</p><p><u>Clinical Studies Examining QTc Interval</u></p><p>A placebo-controlled, randomized, single-dose, crossover study to evaluate the effect on the QTc interval of healthy volunteers was conducted with three oral doses of voriconazole and ketoconazole. The placeboadjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600 mg of voriconazole were 5.1, 4.8, and 8.2 msec, respectively and 7.0 msec for ketoconazole 800 mg. No subject in any group had an increase in QTc of &ge;60 msec from baseline. No subject experienced an interval exceeding the potentially clinically relevant threshold of 500 msec.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetic characteristics</u></p><p>The pharmacokinetics of voriconazole have been characterised in healthy subjects, special populations and patients. During oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or haematopoietic tissue), the observed pharmacokinetic characteristics of rapid and consistent absorption, accumulation and non-linear pharmacokinetics were in agreement with those observed in healthy subjects.</p><p>&nbsp;</p><p>The pharmacokinetics of voriconazole are non-linear due to saturation of its metabolism. Greater than proportional increase in exposure is observed with increasing dose. It is estimated that, on average, increasing the oral dose from 200 mg twice daily to 300 mg twice daily leads to a 2.5-fold increase in exposure (AUC&tau;). The oral maintenance dose of 200 mg (or 100 mg for patients less than 40 kg) achieves a voriconazole exposure similar to 3 mg/kg IV. A 300 mg (or 150 mg for patients less than 40 kg) oral maintenance dose achieves an exposure similar to 4 mg/kg IV. When the recommended intravenous or oral loading dose regimens are administered, plasma concentrations close to steady state are achieved within the first 24 hours of dosing. Without the loading dose, accumulation occurs during twice daily multiple dosing with steady-state plasma voriconazole concentrations being achieved by day 6 in the majority of subjects.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Voriconazole is rapidly and almost completely absorbed following oral administration, with maximum plasma concentrations (Cmax) achieved 1-2 hours after dosing. The absolute bioavailability of voriconazole after oral administration is estimated to be 96 %. When multiple doses of voriconazole are administered with high fat meals, Cmax and AUC&tau; are reduced by 34 % and 24 %, respectively. The absorption of voriconazole is not affected by changes in gastric pH.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution at steady state for voriconazole is estimated to be 4.6 l/kg, suggesting extensive distribution into tissues. Plasma protein binding is estimated to be 58 %. Cerebrospinal fluid samples from eight patients in a compassionate programme showed detectable voriconazole concentrations in all patients.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>In vitro </em>studies showed that voriconazole is metabolised by, the hepatic cytochrome P450 isoenzymes, CYP2C19, CYP2C9 and CYP3A4.</p><p>&nbsp;</p><p>The inter-individual variability of voriconazole pharmacokinetics is high.</p><p><em>&nbsp;</em></p><p><em>In vivo </em>studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20 % of Asian populations may be expected to be poor metabolisers. For Caucasians and Blacks the prevalence of poor metabolisers is 3-5 %. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolisers have, on average, 4-fold higher voriconazole exposure (AUC&tau;) than their homozygous extensive metaboliser counterparts.</p><p>Subjects who are heterozygous extensive metabolisers have on average 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.</p><p>&nbsp;</p><p>The major metabolite of voriconazole is the N-oxide, which accounts for 72 % of the circulating radiolabelled metabolites in plasma. This metabolite has minimal antifungal activity and does not contribute to the overall efficacy of voriconazole.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Voriconazole is eliminated via hepatic metabolism with less than 2 % of the dose excreted unchanged in the urine.</p><p>&nbsp;</p><p>After administration of a radiolabelled dose of voriconazole, approximately 80 % of the radioactivity is recovered in the urine after multiple intravenous dosing and 83 % in the urine after multiple oral dosing. The majority (&gt;94 %) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.</p><p>&nbsp;</p><p>The terminal half-life of voriconazole depends on dose and is approximately 6 hours at 200 mg (orally). Because of non-linear pharmacokinetics, the terminal half-life is not useful in the prediction of the accumulation or elimination of voriconazole.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups</u></p><p><u>Gender</u></p><p>In an oral multiple dose study, Cmax and AUC&tau; for healthy young females were 83 % and 113 % higher, respectively, than in healthy young males (18-45 years)<em>. </em>In the same study, no significant differences in Cmax and AUC&tau; were observed between healthy elderly males and healthy elderly females (&ge;65 years).</p><p>&nbsp;</p><p>In the clinical programme, no dosage adjustment was made on the basis of gender. The safety profile and plasma concentrations observed in male and female patients were similar. Therefore, no dosage adjustment based on gender is necessary.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>In an oral multiple dose study Cmax and AUC&tau; in healthy elderly males (&ge;65 years) were 61 % and 86 % higher, respectively, than in healthy young males (18-45 years). No significant differences in Cmax and AUC&tau; were observed between healthy elderly females (&ge; 65 years) and healthy young females (18- 45 years).</p><p>In the therapeutic studies no dosage adjustment was made on the basis of age. A relationship between plasma concentrations and age was observed. The safety profile of voriconazole in young and elderly patients was similar and, therefore, no dosage adjustment is necessary for the elderly (see section 4.2).</p><p>&nbsp;</p><p><u>Paediatric</u><u>population</u></p><p>The recommended doses in children and adolescent patients are based on a population pharmacokinetic analysis of data obtained from 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescent patients aged 12 to &lt;17 years. Multiple intravenous doses of 3, 4, 6, 7 and 8 mg/kg twice daily and multiple oral doses (using the powder for oral suspension) of 4 mg/kg, 6 mg/kg, and 200 mg twice daily were evaluated in 3 paediatric pharmacokinetic studies. Intravenous loading doses of 6 mg/kg IV twice daily on day 1 followed by 4 mg/kg intravenous dose twice daily and 300 mg oral tablets twice daily were evaluated in one adolescent pharmacokinetic study. Larger inter-subject variability was observed in paediatric patients compared to adults.</p><p>&nbsp;</p><p>A comparison of the paediatric and adult population pharmacokinetic data indicated that the predicted total exposure (AUC&tau;) in children following administration of a 9 mg/kg IV loading dose was comparable to that in adults following a 6 mg/kg IV loading dose. The predicted total exposures in children following IV maintenance doses of 4 and 8 mg/kg twice daily were comparable to those in adults following 3 and 4 mg/kg IV twice daily, respectively. The predicted total exposure in children following an oral maintenance dose of</p><p>9 mg/kg (maximum of 350 mg) twice daily was comparable to that in adults following 200 mg oral twice daily. An 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.</p><p>&nbsp;</p><p>The higher intravenous maintenance dose in paediatric patients relative to adults reflects the higher elimination capacity in paediatric patients due to a greater liver mass to body mass ratio. Oral bioavailability may, however, be limited in paediatric patients with malabsorption and very low body weight for their age.</p><p>In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>Voriconazole exposures in the majority of adolescent patients were comparable to those in adults receiving the same dosing regimens. However, lower voriconazole exposure was observed in some young adolescents with low body weight compared to adults. It is likely that these subjects may metabolize voriconazole more similarly to children than to adults. Based on the population pharmacokinetic analysis, 12- to 14-year-old adolescents weighing less than 50 kg should receive children&rsquo;s doses (see section 4.2).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In an oral single dose (200 mg) study in subjects with normal renal function and mild (creatinine clearance 41-60 ml/min) to severe (creatinine clearance &lt;20 ml/min) renal impairment, the pharmacokinetics of voriconazole were not significantly affected by renal impairment. The plasma protein binding of voriconazole was similar in subjects with different degrees of renal impairment (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>After an oral single dose (200 mg), AUC was 233 % higher in subjects with mild to moderate hepatic cirrhosis (Child-Pugh A and B) compared with subjects with normal hepatic function. Protein binding of voriconazole was not affected by impaired hepatic function.</p><p>&nbsp;</p><p>In an oral multiple dose study, AUC&tau; was similar in subjects with moderate hepatic cirrhosis (Child-Pugh B) given a maintenance dose of 100 mg twice daily and subjects with normal hepatic function given 200 mg twice daily. No pharmacokinetic data are available for patients with severe hepatic cirrhosis (Child-Pugh C) (see sections 4.2 and 4.4).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated-dose toxicity studies with voriconazole indicated the liver to be the target organ. Hepatotoxicity occurred at plasma exposures similar to those obtained at therapeutic doses in humans, in common with other antifungal agents. In rats, mice and dogs, voriconazole also induced minimal adrenal changes.</p><p>Conventional studies of safety pharmacology, genotoxicity or carcinogenic potential did not reveal a special hazard for humans.</p><p>&nbsp;</p><p>In reproduction studies, voriconazole was shown to be teratogenic in rats and embryotoxic in rabbits at systemic exposures equal to those obtained in humans with therapeutic doses. In the pre and postnatal development study in rats at exposures lower than those obtained in humans with therapeutic doses, voriconazole prolonged the duration of gestation and labour and produced dystocia with consequent maternal mortality and reduced perinatal survival of pups. The effects on parturition are probably mediated by species-specific mechanisms, involving reduction of oestradiol levels, and are consistent with those observed with other azole antifungal agents. Voriconazole administration induced no impairment of male or female fertility in rats at exposures similar to those obtained in humans at therapeutic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core</p><p>Lactose monohydrate</p><p>Pregelatinised starch (maize starch)</p><p>Croscarmellose sodium</p><p>Povidone K30</p><p>Silica, colloidal anhydrous</p><p>Magnesium stearate</p><p>&nbsp;</p><p>Film-coating</p><p>HPMC/Hypromellose (3cP, 15cP and 50 cP) (E464)</p><p>Titanium dioxide (E171)</p><p>Lactose monohydrate</p><p>Macrogol4000/PEG (E1521)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 year

Tablet containers: 
Use within 30 days after first opening

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cardboard box containing PVC transparent/Aluminium foil blisters containing 30 film-coated tablets.</p><p>&nbsp;</p><p>Cardboard box containing white opaque HDPE tablet container, with child resistant polypropylene (PP) screw cap and induction seal liner containing 30 film-coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Pharmathen International Greece 
For:
 SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2015.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>